WO2018021333A1 - 骨損傷部位の治療のためのインプラント及びキット、並びに骨損傷部位の治療方法 - Google Patents
骨損傷部位の治療のためのインプラント及びキット、並びに骨損傷部位の治療方法 Download PDFInfo
- Publication number
- WO2018021333A1 WO2018021333A1 PCT/JP2017/026905 JP2017026905W WO2018021333A1 WO 2018021333 A1 WO2018021333 A1 WO 2018021333A1 JP 2017026905 W JP2017026905 W JP 2017026905W WO 2018021333 A1 WO2018021333 A1 WO 2018021333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- porous membrane
- cells
- implant
- bone
- implant according
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 115
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 32
- 206010061728 Bone lesion Diseases 0.000 title abstract 3
- 239000012528 membrane Substances 0.000 claims abstract description 127
- 239000002344 surface layer Substances 0.000 claims abstract description 87
- 239000010410 layer Substances 0.000 claims abstract description 67
- 239000011148 porous material Substances 0.000 claims abstract description 66
- 229920000642 polymer Polymers 0.000 claims abstract description 64
- 239000000560 biocompatible material Substances 0.000 claims abstract description 36
- 238000005192 partition Methods 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 98
- 229920001721 polyimide Polymers 0.000 claims description 85
- 239000004642 Polyimide Substances 0.000 claims description 83
- 210000000988 bone and bone Anatomy 0.000 claims description 68
- 230000006378 damage Effects 0.000 claims description 30
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 claims description 27
- 206010061363 Skeletal injury Diseases 0.000 claims description 24
- 229920005575 poly(amic acid) Polymers 0.000 claims description 23
- 210000002798 bone marrow cell Anatomy 0.000 claims description 21
- 239000004695 Polyether sulfone Substances 0.000 claims description 20
- 150000004985 diamines Chemical class 0.000 claims description 20
- 229920006393 polyether sulfone Polymers 0.000 claims description 20
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- -1 polyetherester Polymers 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 14
- 102000008186 Collagen Human genes 0.000 claims description 13
- 108010035532 Collagen Proteins 0.000 claims description 13
- 229920001436 collagen Polymers 0.000 claims description 13
- 125000006158 tetracarboxylic acid group Chemical group 0.000 claims description 12
- 210000000963 osteoblast Anatomy 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 229920005597 polymer membrane Polymers 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 108010085895 Laminin Proteins 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 36
- 230000007547 defect Effects 0.000 description 30
- 238000012258 culturing Methods 0.000 description 16
- 206010017076 Fracture Diseases 0.000 description 15
- 230000035876 healing Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 208000010392 Bone Fractures Diseases 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- 150000000000 tetracarboxylic acids Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- HLBLWEWZXPIGSM-UHFFFAOYSA-N 4-Aminophenyl ether Chemical compound C1=CC(N)=CC=C1OC1=CC=C(N)C=C1 HLBLWEWZXPIGSM-UHFFFAOYSA-N 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 210000003625 skull Anatomy 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JVERADGGGBYHNP-UHFFFAOYSA-N 5-phenylbenzene-1,2,3,4-tetracarboxylic acid Chemical compound OC(=O)C1=C(C(O)=O)C(C(=O)O)=CC(C=2C=CC=CC=2)=C1C(O)=O JVERADGGGBYHNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 4
- 230000009477 glass transition Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 3
- ZBMISJGHVWNWTE-UHFFFAOYSA-N 3-(4-aminophenoxy)aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(N)=C1 ZBMISJGHVWNWTE-UHFFFAOYSA-N 0.000 description 3
- ICNFHJVPAJKPHW-UHFFFAOYSA-N 4,4'-Thiodianiline Chemical compound C1=CC(N)=CC=C1SC1=CC=C(N)C=C1 ICNFHJVPAJKPHW-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 150000004984 aromatic diamines Chemical group 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- WKDNYTOXBCRNPV-UHFFFAOYSA-N bpda Chemical compound C1=C2C(=O)OC(=O)C2=CC(C=2C=C3C(=O)OC(C3=CC=2)=O)=C1 WKDNYTOXBCRNPV-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical class [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000003455 parietal bone Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- VLDPXPPHXDGHEW-UHFFFAOYSA-N 1-chloro-2-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(Cl)=O VLDPXPPHXDGHEW-UHFFFAOYSA-N 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical group C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 2
- LXJLFVRAWOOQDR-UHFFFAOYSA-N 3-(3-aminophenoxy)aniline Chemical compound NC1=CC=CC(OC=2C=C(N)C=CC=2)=C1 LXJLFVRAWOOQDR-UHFFFAOYSA-N 0.000 description 2
- WWNABCFITWBKEM-UHFFFAOYSA-N 3-[3-(3-aminophenyl)phenyl]aniline Chemical compound NC1=CC=CC(C=2C=C(C=CC=2)C=2C=C(N)C=CC=2)=C1 WWNABCFITWBKEM-UHFFFAOYSA-N 0.000 description 2
- LBPVOEHZEWAJKQ-UHFFFAOYSA-N 3-[4-(3-aminophenoxy)phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=CC(OC=3C=C(N)C=CC=3)=CC=2)=C1 LBPVOEHZEWAJKQ-UHFFFAOYSA-N 0.000 description 2
- POXPSTWTPRGRDO-UHFFFAOYSA-N 3-[4-(3-aminophenyl)phenyl]aniline Chemical compound NC1=CC=CC(C=2C=CC(=CC=2)C=2C=C(N)C=CC=2)=C1 POXPSTWTPRGRDO-UHFFFAOYSA-N 0.000 description 2
- YBRVSVVVWCFQMG-UHFFFAOYSA-N 4,4'-diaminodiphenylmethane Chemical compound C1=CC(N)=CC=C1CC1=CC=C(N)C=C1 YBRVSVVVWCFQMG-UHFFFAOYSA-N 0.000 description 2
- QYIMZXITLDTULQ-UHFFFAOYSA-N 4-(4-amino-2-methylphenyl)-3-methylaniline Chemical group CC1=CC(N)=CC=C1C1=CC=C(N)C=C1C QYIMZXITLDTULQ-UHFFFAOYSA-N 0.000 description 2
- BOVVHULZWVFIOX-UHFFFAOYSA-N 4-[3-(4-aminophenyl)phenyl]aniline Chemical compound C1=CC(N)=CC=C1C1=CC=CC(C=2C=CC(N)=CC=2)=C1 BOVVHULZWVFIOX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001339 alkali metal compounds Chemical class 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- CYIDZMCFTVVTJO-UHFFFAOYSA-N pyromellitic acid Chemical group OC(=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1C(O)=O CYIDZMCFTVVTJO-UHFFFAOYSA-N 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000011824 transgenic rat model Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 1
- RLYCRLGLCUXUPO-UHFFFAOYSA-N 2,6-diaminotoluene Chemical compound CC1=C(N)C=CC=C1N RLYCRLGLCUXUPO-UHFFFAOYSA-N 0.000 description 1
- MXPYJVUYLVNEBB-UHFFFAOYSA-N 2-[2-(2-carboxybenzoyl)oxycarbonylbenzoyl]oxycarbonylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1C(O)=O MXPYJVUYLVNEBB-UHFFFAOYSA-N 0.000 description 1
- HUWXDEQWWKGHRV-UHFFFAOYSA-N 3,3'-Dichlorobenzidine Chemical compound C1=C(Cl)C(N)=CC=C1C1=CC=C(N)C(Cl)=C1 HUWXDEQWWKGHRV-UHFFFAOYSA-N 0.000 description 1
- JFEXPVDGVLNUSC-UHFFFAOYSA-N 3-(3-aminophenyl)sulfanylaniline Chemical compound NC1=CC=CC(SC=2C=C(N)C=CC=2)=C1 JFEXPVDGVLNUSC-UHFFFAOYSA-N 0.000 description 1
- ZMPZWXKBGSQATE-UHFFFAOYSA-N 3-(4-aminophenyl)sulfonylaniline Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=CC(N)=C1 ZMPZWXKBGSQATE-UHFFFAOYSA-N 0.000 description 1
- CKOFBUUFHALZGK-UHFFFAOYSA-N 3-[(3-aminophenyl)methyl]aniline Chemical compound NC1=CC=CC(CC=2C=C(N)C=CC=2)=C1 CKOFBUUFHALZGK-UHFFFAOYSA-N 0.000 description 1
- FGWQCROGAHMWSU-UHFFFAOYSA-N 3-[(4-aminophenyl)methyl]aniline Chemical compound C1=CC(N)=CC=C1CC1=CC=CC(N)=C1 FGWQCROGAHMWSU-UHFFFAOYSA-N 0.000 description 1
- UVUCUHVQYAPMEU-UHFFFAOYSA-N 3-[2-(3-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-yl]aniline Chemical compound NC1=CC=CC(C(C=2C=C(N)C=CC=2)(C(F)(F)F)C(F)(F)F)=C1 UVUCUHVQYAPMEU-UHFFFAOYSA-N 0.000 description 1
- DVXYMCJCMDTSQA-UHFFFAOYSA-N 3-[2-(3-aminophenyl)propan-2-yl]aniline Chemical compound C=1C=CC(N)=CC=1C(C)(C)C1=CC=CC(N)=C1 DVXYMCJCMDTSQA-UHFFFAOYSA-N 0.000 description 1
- WFBKIKKAUTUAHK-UHFFFAOYSA-N 3-[3-(3-aminophenoxy)-4-(trifluoromethyl)phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(OC=3C=C(N)C=CC=3)C(=CC=2)C(F)(F)F)=C1 WFBKIKKAUTUAHK-UHFFFAOYSA-N 0.000 description 1
- GBUNNYTXPDCASY-UHFFFAOYSA-N 3-[3-[2-[3-(3-aminophenoxy)phenyl]-1,1,1,3,3,3-hexafluoropropan-2-yl]phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(C=CC=2)C(C=2C=C(OC=3C=C(N)C=CC=3)C=CC=2)(C(F)(F)F)C(F)(F)F)=C1 GBUNNYTXPDCASY-UHFFFAOYSA-N 0.000 description 1
- FJWUJUIPIZSDTR-UHFFFAOYSA-N 3-[3-[2-[3-(3-aminophenoxy)phenyl]propan-2-yl]phenoxy]aniline Chemical compound C=1C=CC(OC=2C=C(N)C=CC=2)=CC=1C(C)(C)C(C=1)=CC=CC=1OC1=CC=CC(N)=C1 FJWUJUIPIZSDTR-UHFFFAOYSA-N 0.000 description 1
- GZBHMJRTCUJCBO-UHFFFAOYSA-N 3-[3-[3-(3-aminophenoxy)phenoxy]phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(OC=3C=C(OC=4C=C(N)C=CC=4)C=CC=3)C=CC=2)=C1 GZBHMJRTCUJCBO-UHFFFAOYSA-N 0.000 description 1
- MFIONUVRAOILLH-UHFFFAOYSA-N 3-[3-[3-(3-aminophenoxy)phenyl]phenoxy]aniline Chemical group NC1=CC=CC(OC=2C=C(C=CC=2)C=2C=C(OC=3C=C(N)C=CC=3)C=CC=2)=C1 MFIONUVRAOILLH-UHFFFAOYSA-N 0.000 description 1
- SABXTRNPHKCTFO-UHFFFAOYSA-N 3-[3-[3-(3-aminophenoxy)phenyl]sulfanylphenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(SC=3C=C(OC=4C=C(N)C=CC=4)C=CC=3)C=CC=2)=C1 SABXTRNPHKCTFO-UHFFFAOYSA-N 0.000 description 1
- YLTIRYJAWQHSQS-UHFFFAOYSA-N 3-[3-[3-(3-aminophenoxy)phenyl]sulfonylphenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(C=CC=2)S(=O)(=O)C=2C=C(OC=3C=C(N)C=CC=3)C=CC=2)=C1 YLTIRYJAWQHSQS-UHFFFAOYSA-N 0.000 description 1
- OLFCXXUMDWEXKG-UHFFFAOYSA-N 3-[3-[[3-(3-aminophenoxy)phenyl]methyl]phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=C(CC=3C=C(OC=4C=C(N)C=CC=4)C=CC=3)C=CC=2)=C1 OLFCXXUMDWEXKG-UHFFFAOYSA-N 0.000 description 1
- NYRFBMFAUFUULG-UHFFFAOYSA-N 3-[4-[2-[4-(3-aminophenoxy)phenyl]propan-2-yl]phenoxy]aniline Chemical compound C=1C=C(OC=2C=C(N)C=CC=2)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=CC(N)=C1 NYRFBMFAUFUULG-UHFFFAOYSA-N 0.000 description 1
- NQZOFDAHZVLQJO-UHFFFAOYSA-N 3-[4-[4-(3-aminophenoxy)phenoxy]phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=CC(OC=3C=CC(OC=4C=C(N)C=CC=4)=CC=3)=CC=2)=C1 NQZOFDAHZVLQJO-UHFFFAOYSA-N 0.000 description 1
- UCQABCHSIIXVOY-UHFFFAOYSA-N 3-[4-[4-(3-aminophenoxy)phenyl]phenoxy]aniline Chemical group NC1=CC=CC(OC=2C=CC(=CC=2)C=2C=CC(OC=3C=C(N)C=CC=3)=CC=2)=C1 UCQABCHSIIXVOY-UHFFFAOYSA-N 0.000 description 1
- JERFEOKUSPGKGV-UHFFFAOYSA-N 3-[4-[4-(3-aminophenoxy)phenyl]sulfanylphenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=CC(SC=3C=CC(OC=4C=C(N)C=CC=4)=CC=3)=CC=2)=C1 JERFEOKUSPGKGV-UHFFFAOYSA-N 0.000 description 1
- WCXGOVYROJJXHA-UHFFFAOYSA-N 3-[4-[4-(3-aminophenoxy)phenyl]sulfonylphenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC(OC=3C=C(N)C=CC=3)=CC=2)=C1 WCXGOVYROJJXHA-UHFFFAOYSA-N 0.000 description 1
- YSMXOEWEUZTWAK-UHFFFAOYSA-N 3-[4-[[4-(3-aminophenoxy)phenyl]methyl]phenoxy]aniline Chemical compound NC1=CC=CC(OC=2C=CC(CC=3C=CC(OC=4C=C(N)C=CC=4)=CC=3)=CC=2)=C1 YSMXOEWEUZTWAK-UHFFFAOYSA-N 0.000 description 1
- WECDUOXQLAIPQW-UHFFFAOYSA-N 4,4'-Methylene bis(2-methylaniline) Chemical compound C1=C(N)C(C)=CC(CC=2C=C(C)C(N)=CC=2)=C1 WECDUOXQLAIPQW-UHFFFAOYSA-N 0.000 description 1
- YARZEPAVWOMMHZ-UHFFFAOYSA-N 4-(3,4-dicarboxy-4-phenylcyclohexa-1,5-dien-1-yl)phthalic acid Chemical compound OC(=O)C1C=C(C=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC1(C(O)=O)C1=CC=CC=C1 YARZEPAVWOMMHZ-UHFFFAOYSA-N 0.000 description 1
- VILWHDNLOJCHNJ-UHFFFAOYSA-N 4-(3,4-dicarboxyphenyl)sulfanylphthalic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC=C1SC1=CC=C(C(O)=O)C(C(O)=O)=C1 VILWHDNLOJCHNJ-UHFFFAOYSA-N 0.000 description 1
- XCCLXQMGBRGRLM-UHFFFAOYSA-N 4-(3-propylphenoxy)aniline Chemical compound CCCC1=CC=CC(OC=2C=CC(N)=CC=2)=C1 XCCLXQMGBRGRLM-UHFFFAOYSA-N 0.000 description 1
- QNLCDRXVEPWSBQ-UHFFFAOYSA-N 4-(4,5-dicarboxy-5-phenylcyclohexa-1,3-dien-1-yl)phthalic acid Chemical compound OC(=O)C1=CC=C(C=2C=C(C(C(O)=O)=CC=2)C(O)=O)CC1(C(O)=O)C1=CC=CC=C1 QNLCDRXVEPWSBQ-UHFFFAOYSA-N 0.000 description 1
- MITHMOYLTXMLRB-UHFFFAOYSA-N 4-(4-aminophenyl)sulfinylaniline Chemical compound C1=CC(N)=CC=C1S(=O)C1=CC=C(N)C=C1 MITHMOYLTXMLRB-UHFFFAOYSA-N 0.000 description 1
- IWXCYYWDGDDPAC-UHFFFAOYSA-N 4-[(3,4-dicarboxyphenyl)methyl]phthalic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC=C1CC1=CC=C(C(O)=O)C(C(O)=O)=C1 IWXCYYWDGDDPAC-UHFFFAOYSA-N 0.000 description 1
- OMHOXRVODFQGCA-UHFFFAOYSA-N 4-[(4-amino-3,5-dimethylphenyl)methyl]-2,6-dimethylaniline Chemical compound CC1=C(N)C(C)=CC(CC=2C=C(C)C(N)=C(C)C=2)=C1 OMHOXRVODFQGCA-UHFFFAOYSA-N 0.000 description 1
- GEYAGBVEAJGCFB-UHFFFAOYSA-N 4-[2-(3,4-dicarboxyphenyl)propan-2-yl]phthalic acid Chemical compound C=1C=C(C(O)=O)C(C(O)=O)=CC=1C(C)(C)C1=CC=C(C(O)=O)C(C(O)=O)=C1 GEYAGBVEAJGCFB-UHFFFAOYSA-N 0.000 description 1
- JYZPDAUOQGFBKT-UHFFFAOYSA-N 4-[2-[2-[2-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=CC=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=1C(C)(C)C1=CC=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 JYZPDAUOQGFBKT-UHFFFAOYSA-N 0.000 description 1
- GQUSLIBGUTZKJZ-UHFFFAOYSA-N 4-[3-(3,4-dicarboxyphenoxy)phenoxy]phthalic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC=C1OC1=CC=CC(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)=C1 GQUSLIBGUTZKJZ-UHFFFAOYSA-N 0.000 description 1
- WUPRYUDHUFLKFL-UHFFFAOYSA-N 4-[3-(4-aminophenoxy)phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(OC=2C=CC(N)=CC=2)=C1 WUPRYUDHUFLKFL-UHFFFAOYSA-N 0.000 description 1
- WJMZKMOQJDOAIE-UHFFFAOYSA-N 4-[3-[2-[3-(4-aminophenoxy)phenyl]-1,1,1,3,3,3-hexafluoropropan-2-yl]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(C(C=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)(C(F)(F)F)C(F)(F)F)=C1 WJMZKMOQJDOAIE-UHFFFAOYSA-N 0.000 description 1
- HCJSCAOEKCHDQO-UHFFFAOYSA-N 4-[3-[3-(4-aminophenoxy)phenoxy]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(OC=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 HCJSCAOEKCHDQO-UHFFFAOYSA-N 0.000 description 1
- WVIGQQBEFCXWRW-UHFFFAOYSA-N 4-[3-[3-(4-aminophenoxy)phenyl]phenoxy]aniline Chemical group C1=CC(N)=CC=C1OC1=CC=CC(C=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 WVIGQQBEFCXWRW-UHFFFAOYSA-N 0.000 description 1
- LEUQLXVKRVZUEX-UHFFFAOYSA-N 4-[3-[3-(4-aminophenoxy)phenyl]sulfanylphenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(SC=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 LEUQLXVKRVZUEX-UHFFFAOYSA-N 0.000 description 1
- VZZOONBAZHZSEB-UHFFFAOYSA-N 4-[3-[3-(4-aminophenoxy)phenyl]sulfonylphenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(S(=O)(=O)C=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 VZZOONBAZHZSEB-UHFFFAOYSA-N 0.000 description 1
- IXZCKKLBICAHRA-UHFFFAOYSA-N 4-[3-[[3-(4-aminophenoxy)phenyl]methyl]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(CC=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 IXZCKKLBICAHRA-UHFFFAOYSA-N 0.000 description 1
- NQZSNMFBZVBKRE-UHFFFAOYSA-N 4-[4-(3,4-dicarboxyphenoxy)-4-phenylcyclohexa-1,5-dien-1-yl]oxyphthalic acid Chemical group C1=C(C(O)=O)C(C(=O)O)=CC=C1OC(C=C1)=CCC1(C=1C=CC=CC=1)OC1=CC=C(C(O)=O)C(C(O)=O)=C1 NQZSNMFBZVBKRE-UHFFFAOYSA-N 0.000 description 1
- JCRRFJIVUPSNTA-UHFFFAOYSA-N 4-[4-(4-aminophenoxy)phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC(C=C1)=CC=C1OC1=CC=C(N)C=C1 JCRRFJIVUPSNTA-UHFFFAOYSA-N 0.000 description 1
- QBSMHWVGUPQNJJ-UHFFFAOYSA-N 4-[4-(4-aminophenyl)phenyl]aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(C=2C=CC(N)=CC=2)C=C1 QBSMHWVGUPQNJJ-UHFFFAOYSA-N 0.000 description 1
- HHLMWQDRYZAENA-UHFFFAOYSA-N 4-[4-[2-[4-(4-aminophenoxy)phenyl]-1,1,1,3,3,3-hexafluoropropan-2-yl]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=C(C(C=2C=CC(OC=3C=CC(N)=CC=3)=CC=2)(C(F)(F)F)C(F)(F)F)C=C1 HHLMWQDRYZAENA-UHFFFAOYSA-N 0.000 description 1
- KMKWGXGSGPYISJ-UHFFFAOYSA-N 4-[4-[2-[4-(4-aminophenoxy)phenyl]propan-2-yl]phenoxy]aniline Chemical compound C=1C=C(OC=2C=CC(N)=CC=2)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(N)C=C1 KMKWGXGSGPYISJ-UHFFFAOYSA-N 0.000 description 1
- LDFYRFKAYFZVNH-UHFFFAOYSA-N 4-[4-[4-(4-aminophenoxy)phenoxy]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC(C=C1)=CC=C1OC(C=C1)=CC=C1OC1=CC=C(N)C=C1 LDFYRFKAYFZVNH-UHFFFAOYSA-N 0.000 description 1
- HYDATEKARGDBKU-UHFFFAOYSA-N 4-[4-[4-(4-aminophenoxy)phenyl]phenoxy]aniline Chemical group C1=CC(N)=CC=C1OC1=CC=C(C=2C=CC(OC=3C=CC(N)=CC=3)=CC=2)C=C1 HYDATEKARGDBKU-UHFFFAOYSA-N 0.000 description 1
- SXTPNMJRVQKNRN-UHFFFAOYSA-N 4-[4-[4-(4-aminophenoxy)phenyl]sulfanylphenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC(C=C1)=CC=C1SC(C=C1)=CC=C1OC1=CC=C(N)C=C1 SXTPNMJRVQKNRN-UHFFFAOYSA-N 0.000 description 1
- UTDAGHZGKXPRQI-UHFFFAOYSA-N 4-[4-[4-(4-aminophenoxy)phenyl]sulfonylphenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=C(S(=O)(=O)C=2C=CC(OC=3C=CC(N)=CC=3)=CC=2)C=C1 UTDAGHZGKXPRQI-UHFFFAOYSA-N 0.000 description 1
- PJCCVNKHRXIAHZ-UHFFFAOYSA-N 4-[4-[[4-(4-aminophenoxy)phenyl]methyl]phenoxy]aniline Chemical compound C1=CC(N)=CC=C1OC(C=C1)=CC=C1CC(C=C1)=CC=C1OC1=CC=C(N)C=C1 PJCCVNKHRXIAHZ-UHFFFAOYSA-N 0.000 description 1
- NVKGJHAQGWCWDI-UHFFFAOYSA-N 4-[4-amino-2-(trifluoromethyl)phenyl]-3-(trifluoromethyl)aniline Chemical group FC(F)(F)C1=CC(N)=CC=C1C1=CC=C(N)C=C1C(F)(F)F NVKGJHAQGWCWDI-UHFFFAOYSA-N 0.000 description 1
- XPAQFJJCWGSXGJ-UHFFFAOYSA-N 4-amino-n-(4-aminophenyl)benzamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=C(N)C=C1 XPAQFJJCWGSXGJ-UHFFFAOYSA-N 0.000 description 1
- VQVIHDPBMFABCQ-UHFFFAOYSA-N 5-(1,3-dioxo-2-benzofuran-5-carbonyl)-2-benzofuran-1,3-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC(C(C=2C=C3C(=O)OC(=O)C3=CC=2)=O)=C1 VQVIHDPBMFABCQ-UHFFFAOYSA-N 0.000 description 1
- QHHKLPCQTTWFSS-UHFFFAOYSA-N 5-[2-(1,3-dioxo-2-benzofuran-5-yl)-1,1,1,3,3,3-hexafluoropropan-2-yl]-2-benzofuran-1,3-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC(C(C=2C=C3C(=O)OC(=O)C3=CC=2)(C(F)(F)F)C(F)(F)F)=C1 QHHKLPCQTTWFSS-UHFFFAOYSA-N 0.000 description 1
- BBTGUNMUUYNPLH-UHFFFAOYSA-N 5-[4-[(1,3-dioxo-2-benzofuran-5-yl)oxy]phenoxy]-2-benzofuran-1,3-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC(OC2=CC=C(C=C2)OC=2C=C3C(=O)OC(C3=CC=2)=O)=C1 BBTGUNMUUYNPLH-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- KLNAXSUBGHKVBE-UHFFFAOYSA-N COC1=C(C=CC(=C1)N)C1=C(C=C(N)C=C1)OC.COC=1C=C(C=CC1N)C1=CC(=C(N)C=C1)OC Chemical compound COC1=C(C=CC(=C1)N)C1=C(C=C(N)C=C1)OC.COC=1C=C(C=CC1N)C1=CC(=C(N)C=C1)OC KLNAXSUBGHKVBE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000003044 Closed Fractures Diseases 0.000 description 1
- 206010010149 Complicated fracture Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- VCCBEIPGXKNHFW-UHFFFAOYSA-N biphenyl-4,4'-diol Chemical compound C1=CC(O)=CC=C1C1=CC=C(O)C=C1 VCCBEIPGXKNHFW-UHFFFAOYSA-N 0.000 description 1
- KYJFTSJZXHMIEL-UHFFFAOYSA-N bis(3-amino-4-chlorophenyl)methanone Chemical compound C1=C(Cl)C(N)=CC(C(=O)C=2C=C(N)C(Cl)=CC=2)=C1 KYJFTSJZXHMIEL-UHFFFAOYSA-N 0.000 description 1
- BQHONQTZEHHWKX-UHFFFAOYSA-N bis(3-amino-4-methoxyphenyl)methanone Chemical compound C1=C(N)C(OC)=CC=C1C(=O)C1=CC=C(OC)C(N)=C1 BQHONQTZEHHWKX-UHFFFAOYSA-N 0.000 description 1
- TUQQUUXMCKXGDI-UHFFFAOYSA-N bis(3-aminophenyl)methanone Chemical compound NC1=CC=CC(C(=O)C=2C=C(N)C=CC=2)=C1 TUQQUUXMCKXGDI-UHFFFAOYSA-N 0.000 description 1
- CCTYCLLYQJOQSB-UHFFFAOYSA-N bis[3-(3-aminophenoxy)phenyl]methanone Chemical compound NC1=CC=CC(OC=2C=C(C=CC=2)C(=O)C=2C=C(OC=3C=C(N)C=CC=3)C=CC=2)=C1 CCTYCLLYQJOQSB-UHFFFAOYSA-N 0.000 description 1
- QELIUXRUDBKNAP-UHFFFAOYSA-N bis[3-(4-aminophenoxy)phenyl]methanone Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(C(=O)C=2C=C(OC=3C=CC(N)=CC=3)C=CC=2)=C1 QELIUXRUDBKNAP-UHFFFAOYSA-N 0.000 description 1
- VPCCFJZBAILZNL-UHFFFAOYSA-N bis[3-amino-4-(4-phenylphenoxy)phenyl]methanone Chemical compound NC1=CC(C(=O)C=2C=C(N)C(OC=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=2)=CC=C1OC(C=C1)=CC=C1C1=CC=CC=C1 VPCCFJZBAILZNL-UHFFFAOYSA-N 0.000 description 1
- BBRLKRNNIMVXOD-UHFFFAOYSA-N bis[4-(3-aminophenoxy)phenyl]methanone Chemical compound NC1=CC=CC(OC=2C=CC(=CC=2)C(=O)C=2C=CC(OC=3C=C(N)C=CC=3)=CC=2)=C1 BBRLKRNNIMVXOD-UHFFFAOYSA-N 0.000 description 1
- LSDYQEILXDCDTR-UHFFFAOYSA-N bis[4-(4-aminophenoxy)phenyl]methanone Chemical compound C1=CC(N)=CC=C1OC1=CC=C(C(=O)C=2C=CC(OC=3C=CC(N)=CC=3)=CC=2)C=C1 LSDYQEILXDCDTR-UHFFFAOYSA-N 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000011300 coal pitch Substances 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- DOBFTMLCEYUAQC-UHFFFAOYSA-N naphthalene-2,3,6,7-tetracarboxylic acid Chemical compound OC(=O)C1=C(C(O)=O)C=C2C=C(C(O)=O)C(C(=O)O)=CC2=C1 DOBFTMLCEYUAQC-UHFFFAOYSA-N 0.000 description 1
- YTVNOVQHSGMMOV-UHFFFAOYSA-N naphthalenetetracarboxylic dianhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=C2C(=O)OC(=O)C1=C32 YTVNOVQHSGMMOV-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000011301 petroleum pitch Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2846—Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4603—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/02—Layer formed of wires, e.g. mesh
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/18—Layered products comprising a layer of metal comprising iron or steel
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/28—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42
- B32B27/281—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42 comprising polyimides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/28—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42
- B32B27/285—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42 comprising polyethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/28—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42
- B32B27/286—Layered products comprising a layer of synthetic resin comprising synthetic resins not wholly covered by any one of the sub-groups B32B27/30 - B32B27/42 comprising polysulphones; polysulfides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/26—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/30769—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth madreporic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30772—Apertures or holes, e.g. of circular cross section
- A61F2002/30784—Plurality of holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30907—Nets or sleeves applied to surface of prostheses or in cement
- A61F2002/30909—Nets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/10—Coating on the layer surface on synthetic resin layer or on natural or synthetic rubber layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/26—Polymeric coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/40—Properties of the layers or laminate having particular optical properties
- B32B2307/402—Coloured
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/732—Dimensional properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2535/00—Medical equipment, e.g. bandage, prostheses or catheter
Definitions
- the present invention relates to an implant and a kit for treating a bone damaged site, and a method for treating a bone damaged site.
- Non-patent Document 1 Patent Document 1
- titanium mesh is used for many bone injuries and oral disease treatments because of its characteristics of high robustness, flexibility and life compatibility. Although titanium mesh can provide a stable wound healing space, it does not itself have a bone damage healing effect.
- Polyimide Porous Membrane The polyimide porous membrane has been used for applications such as filters, low dielectric constant films, electrolyte membranes for fuel cells, etc., especially for battery-related applications before the present application.
- Patent Documents 4 to 6 are particularly excellent in permeability of substances such as gas, high porosity, excellent smoothness of both surfaces, relatively high strength, and in the direction of film thickness despite high porosity.
- a polyimide porous membrane having a large number of macrovoids having excellent proof stress against compressive stress is described. These are all polyimide porous membranes prepared via an amic acid.
- a cell culturing method has been reported that includes culturing cells by applying them to a polyimide porous membrane (Patent Document 7).
- the object of the present invention is to provide a simple and effective means of treating bone damage that is compatible with various wound surfaces.
- the present inventors have found that a polymer porous membrane having a three-dimensional structure similar to a bone marrow structure can promote healing of a bone damage site. Moreover, it discovered that a cell has the outstanding proliferation ability on the said polymer porous membrane.
- the present inventors further improve the proliferation ability of these cells by combining a biopolymer such as collagen generally used for culturing mesenchymal stem cells and osteoblasts and the above-mentioned polymer porous membrane.
- a biopolymer such as collagen generally used for culturing mesenchymal stem cells and osteoblasts and the above-mentioned polymer porous membrane. The inventors have found that this is possible and have reached the present invention.
- An implant for treatment of a bone injury site comprising a polymer porous membrane and a layer containing a biocompatible material, wherein the polymer porous membrane includes a surface layer A and a surface layer B having a plurality of pores.
- the implant in which the holes in the surface layers A and B communicate with the macrovoid.
- the biocompatible material is collagen, silicone, fibronectin, laminin, polylysine, polylactide, polyglycolide, polycaprolactone, polyhydroxybutyrate, polylactide-co-caprolactone, polycarbonate, biodegradable polyurethane, polyetherester, polyesteramide,
- the implant according to [8], wherein the polyimide porous film is a polyimide porous film containing polyimide obtained from tetracarboxylic dianhydride and diamine.
- the polyimide porous membrane was colored by heat treatment at 250 ° C. or higher after molding a polyamic acid solution composition containing a polyamic acid solution obtained from tetracarboxylic dianhydride and diamine and a colored precursor.
- the implant according to [12], wherein the cell is a bone marrow cell, a mesenchymal stem cell, a fibroblast, an osteoblast, or a cell derived therefrom.
- the metal mesh is composed of titanium, stainless steel, titanium-coated steel, titanium nitride, or a combination thereof.
- Bone damage treatment kit including materials necessary for bone damage treatment and an instruction manual.
- a method for treating a bone injury site comprising applying the implant according to any one of [15] to the bone injury site.
- the polymer porous membrane used in the present invention is flexible and can hold and grow cells in its inherent three-dimensional structure. It is also possible to promote the treatment of the bone damage site by supporting the cell according to the purpose on the porous polymer membrane and applying it to the bone damage site. In addition, by combining a biopolymer such as collagen used for culturing mesenchymal stem cells and osteoblasts with a polymer porous membrane, the proliferation ability of these cells can be further improved, and bone damage sites can be improved. It is possible to further promote treatment. Moreover, when cells concentrate on the polymer porous membrane, cells in the vicinity of the wound surface increase and bone formation can be promoted.
- FIG. 1 shows a scanning electron micrograph of a polyimide porous membrane having a bone marrow-like structure. It is a scanning electron micrograph of the cross section of a polyimide porous membrane, and A surface (mesh structure surface) and B surface (large hole structure surface). As a comparison, a scanning electron micrograph of bone marrow is shown (panel (b)).
- FIG. 2 shows a rat skull defect model.
- FIG. 3 shows a photograph of a technique for covering a defect site with a polyimide porous membrane sheet in a rat skull defect model.
- FIG. 4 shows the healing of bone damage when a polyimide porous membrane is applied to the bone damage site of the rat skull defect model.
- FIG. 1 shows a scanning electron micrograph of a polyimide porous membrane having a bone marrow-like structure. It is a scanning electron micrograph of the cross section of a polyimide porous membrane, and A surface (mesh structure surface) and B surface (large hole structure surface). As
- FIG. 5 shows the healing of bone damage when a polyimide porous membrane supported by seeding and culturing bone marrow cells once is applied to a bone damage site of a rat skull defect model.
- FIG. 6 shows the time course of new bone volume (BV) when a polyimide porous membrane supported by seeding and culturing bone marrow cells once or twice is applied to a bone injury site in a rat skull defect model.
- BV new bone volume
- FIG. 7 shows changes over time in bone mineral content (BMC) when a polyimide porous membrane supported by culturing bone marrow cells once or twice at a bone injury site in a rat skull defect model is applied.
- BMC bone mineral content
- FIG. 8 shows changes over time in bone density (BMD) when a polyimide porous membrane supported by culturing bone marrow cells once or twice is applied to a bone injury site of a rat skull defect model.
- FIG. 9 shows time-dependent changes in the number of cells when osteoblasts are cultured on Teldermis (registered trademark) and on a composite material of a porous polyimide membrane and Teldermis (registered trademark).
- One aspect of the present invention is an implant for treatment of a bone injury site, including a polymer porous membrane and a layer containing a biocompatible material, wherein the polymer porous membrane has a plurality of pores.
- a porous polymer membrane having a three-layer structure having a layer A and a surface layer B, and a macrovoid layer sandwiched between the surface layer A and the surface layer B, wherein the pores existing in the surface layer A
- the average pore diameter is smaller than the average pore diameter of the pores existing in the surface layer B, and the macrovoid layer is surrounded by the partition walls bonded to the surface layers A and B, the partition walls, and the surface layers A and B.
- the implant has a plurality of macrovoids, and the holes in the surface layers A and B communicate with the macrovoids.
- the implant is also referred to below as “implant of the invention”.
- an “implant” refers to an article or device that is completely or partially placed in the body of an animal, for example, by a surgical procedure or a minimally invasive method.
- bone damage means a state in which bone tissue is damaged due to trauma, fatigue, disease, etc., for example, a state in which only the surface of the bone tissue is damaged, fracture, bone Including defects.
- fracture includes a complete fracture in which the bone has completely lost continuity, and a failed fracture in which the bone has not completely lost continuity. Fracture modes include closed fractures (simple fractures) where the fracture is not open to the outside of the body, open fractures (complex fracture) where the fracture is open to the outside of the body, and one bone is separated only at one location. There are two types of fractures, such as single fractures and multiple fractures in which one bone is cut off at multiple points.
- the implant of the present invention may be applied to any form of fracture.
- treatment of a bone damaged site means that the damaged state of a bone damaged site is partially or totally improved, repaired, or recovered.
- Treatment of a fracture site refers to partial or complete improvement, repair, or recovery of a site where a bone has been cut off or a site where a bone is missing.
- promoting treatment of bone damage refers to shortening the period for improving, repairing, or recovering the damaged state of a bone damaged site, or improving the site where the damaged state is improved, repaired, or recovered. It means expanding.
- Indications for treatment of bone injury site or promotion of treatment include fractured bone adhesion, reduction of bone defect area or volume, bone density (Bone Mineral Density. BMD), bone mineral content (Bone Mineral Content. BMC), Bone mass (Bone Mass), new bone volume (BV), etc. can be used as appropriate.
- the average pore diameter of the pores existing in the surface layer A (hereinafter also referred to as “A plane” or “mesh plane”) in the polymer porous membrane used in the implant of the present invention is not particularly limited. 0.01 ⁇ m or more and less than 200 ⁇ m, 0.01 to 150 ⁇ m, 0.01 to 100 ⁇ m, 0.01 to 50 ⁇ m, 0.01 ⁇ m to 40 ⁇ m, 0.01 ⁇ m to 30 ⁇ m, 0.01 ⁇ m to 20 ⁇ m, or 0.01 ⁇ m to 15 ⁇ m
- the thickness is preferably 0.01 ⁇ m to 15 ⁇ m.
- the average pore diameter of the pores existing in the surface layer B (hereinafter also referred to as “B surface” or “large hole surface”) in the polymer porous membrane used in the implant of the present invention is the number of pores existing in the surface layer A.
- B surface or “large hole surface”
- it is, for example, more than 5 ⁇ m and 200 ⁇ m or less, 20 ⁇ m to 100 ⁇ m, 30 ⁇ m to 100 ⁇ m, 40 ⁇ m to 100 ⁇ m, 50 ⁇ m to 100 ⁇ m, or 60 ⁇ m to 100 ⁇ m, and preferably 20 ⁇ m to 100 ⁇ m.
- the average pore diameter on the surface of the polymer porous membrane is determined by measuring the pore area for 200 or more apertures from the scanning electron micrograph on the surface of the porous membrane, and determining the pore size according to the following formula (1)
- the average diameter when the shape is assumed to be a perfect circle can be obtained by calculation.
- Sa means the average value of the pore area.
- the thickness of the surface layers A and B is not particularly limited, but is, for example, 0.01 to 50 ⁇ m, preferably 0.01 to 20 ⁇ m.
- the average pore diameter in the plane direction of the macrovoids in the macrovoid layer in the polymer porous membrane is not particularly limited, but is, for example, 10 to 500 ⁇ m, preferably 10 to 100 ⁇ m, and more preferably 10 to 80 ⁇ m.
- the thickness of the partition wall in the macrovoid layer is not particularly limited, but is, for example, 0.01 to 50 ⁇ m, and preferably 0.01 to 20 ⁇ m.
- at least one partition wall in the macrovoid layer has one or more average pore diameters of 0.01 to 100 ⁇ m, preferably 0.01 to 50 ⁇ m, communicating adjacent macrovoids. Has holes.
- the partition in the macrovoid layer has no pores.
- the film thickness of the polymer porous membrane used in the implant of the present invention is not particularly limited, but may be 5 ⁇ m or more, 10 ⁇ m or more, 20 ⁇ m or more, or 25 ⁇ m or more, 500 ⁇ m or less, 300 ⁇ m or less, 100 ⁇ m or less, 75 ⁇ m or less. Or 50 micrometers or less may be sufficient.
- the thickness is preferably 5 to 500 ⁇ m, more preferably 25 to 75 ⁇ m.
- the measurement of the thickness of the polymer porous membrane used in the implant of the present invention can be performed with a contact-type thickness meter.
- the porosity of the polymer porous membrane used in the implant of the present invention is not particularly limited, but is, for example, 40% or more and less than 95%.
- the porosity of the polymer porous membrane used in the implant of the present invention can be determined from the mass per unit area according to the following formula (2) by measuring the thickness and mass of the porous film cut to a predetermined size.
- S represents the area of the porous film
- d represents the film thickness
- w represents the measured mass
- D represents the density of the polymer.
- the density is 1.34 g / cm 3 . To do.
- the polymer porous membrane used in the present invention is preferably a three-layer structure having a surface layer A and a surface layer B having a plurality of pores, and a macrovoid layer sandwiched between the surface layer A and the surface layer B.
- the macrovoid layer includes a partition bonded to the surface layers A and B, and a plurality of macrovoids surrounded by the partition and the surface layers A and B.
- the partition of the macrovoid layer and the surface The thicknesses of the layers A and B are 0.01 to 20 ⁇ m, the holes in the surface layers A and B communicate with the macrovoids, the total film thickness is 5 to 500 ⁇ m, and the porosity is 40% or more. Less than 95% Is mer porous membrane.
- the at least one partition wall in the macrovoid layer has one or more pores having an average pore diameter of 0.01 to 100 ⁇ m, preferably 0.01 to 50 ⁇ m, communicating between adjacent macrovoids. Have In another embodiment, the septum does not have such holes.
- the polymer porous membrane used in the implant of the present invention is preferably sterilized.
- the sterilization treatment is not particularly limited, and includes any sterilization treatment such as dry heat sterilization, steam sterilization, sterilization with a disinfectant such as ethanol, and electromagnetic wave sterilization such as ultraviolet rays and gamma rays.
- the polymer porous membrane used in the implant of the present invention is not particularly limited as long as it has the above structural characteristics, but is preferably a porous membrane of polyimide or polyethersulfone (PES).
- PES polyethersulfone
- Polyimide is a general term for polymers containing imide bonds in repeating units, and usually means an aromatic polyimide in which aromatic compounds are directly linked by imide bonds.
- Aromatic polyimide has a conjugated structure through the imide bond between aromatic and aromatic, so it has a rigid and strong molecular structure, and the imide bond has a strong intermolecular force, so it has a very high level of heat. Has mechanical, mechanical and chemical properties.
- the polyimide porous membrane that can be used in the implant of the present invention is preferably a polyimide porous membrane containing polyimide (as a main component) obtained from tetracarboxylic dianhydride and diamine, more preferably tetracarboxylic acid. It is a polyimide porous membrane made of polyimide obtained from dianhydride and diamine. “Containing as a main component” means that a component other than polyimide obtained from tetracarboxylic dianhydride and diamine may be essentially not included or included as a component of the polyimide porous membrane. It means that it is an additional component that does not affect the properties of the polyimide obtained from tetracarboxylic dianhydride and diamine.
- a polyamic acid solution composition comprising a polyamic acid solution obtained from a tetracarboxylic acid component and a diamine component and a colored precursor
- a colored polyimide porous membrane obtained by heat treatment at 250 ° C. or higher is also included.
- Polyamic acid is obtained by polymerizing a tetracarboxylic acid component and a diamine component.
- Polyamic acid is a polyimide precursor that can be ring-closed to form polyimide by thermal imidization or chemical imidization.
- the polyamic acid even if a part of the amic acid is imidized, it can be used as long as it does not affect the present invention. That is, the polyamic acid may be partially thermally imidized or chemically imidized.
- fine particles such as an imidization catalyst, an organic phosphorus-containing compound, inorganic fine particles, and organic fine particles can be added to the polyamic acid solution as necessary.
- fine particles such as a chemical imidating agent, a dehydrating agent, inorganic fine particles, and organic fine particles, etc. can be added to a polyamic acid solution as needed. Even when the above components are added to the polyamic acid solution, it is preferable that the coloring precursor is not precipitated.
- colored precursor means a precursor that is partially or wholly carbonized by heat treatment at 250 ° C. or higher to produce a colored product.
- the colored precursor that can be used in the production of the polyimide porous membrane is uniformly dissolved or dispersed in a polyamic acid solution or a polyimide solution, 250 ° C. or higher, preferably 260 ° C. or higher, more preferably 280 ° C. or higher, more preferably Is thermally decomposed and carbonized by heat treatment at 300 ° C. or higher, preferably 250 ° C. or higher in the presence of oxygen such as air, preferably 260 ° C. or higher, more preferably 280 ° C. or higher, more preferably 300 ° C. or higher.
- Those that produce colored products are preferred, those that produce black colored products are more preferred, and carbon-based colored precursors are more preferred.
- the carbon-based coloring precursor is not particularly limited.
- polymers such as petroleum tar, petroleum pitch, coal tar, coal pitch, or polymers obtained from monomers including pitch, coke, and acrylonitrile, ferrocene compounds (ferrocene and ferrocene derivatives). Etc.
- the polymer and / or ferrocene compound obtained from the monomer containing acrylonitrile are preferable, and polyacrylonitrile is preferable as a polymer obtained from the monomer containing acrylonitrile.
- the polyimide porous membrane that can be used in the present invention is obtained by molding a polyamic acid solution obtained from a tetracarboxylic acid component and a diamine component without using the above colored precursor, A polyimide porous membrane obtained by heat treatment is also included.
- a polyimide porous membrane produced without using a colored precursor is composed of, for example, 3 to 60% by mass of a polyamic acid having an intrinsic viscosity of 1.0 to 3.0 and 40 to 97% by mass of an organic polar solvent.
- the polyamic acid solution is cast into a film and immersed in or contacted with a coagulation solvent containing water as an essential component to produce a polyamic acid porous film, and then the polyamic acid porous film is heat-treated to form an imide. May be manufactured.
- the coagulation solvent containing water as an essential component is water or a mixed solution of 5% by mass or more and less than 100% by mass of water and more than 0% by mass and 95% by mass or less of an organic polar solvent. May be.
- plasma treatment may be performed on at least one surface of the obtained porous polyimide film.
- any tetracarboxylic dianhydride can be used, and can be appropriately selected according to desired characteristics.
- Specific examples of tetracarboxylic dianhydride include pyromellitic dianhydride, 3,3 ′, 4,4′-biphenyltetracarboxylic dianhydride (s-BPDA), 2,3,3 ′, 4 ′.
- -Biphenyltetracarboxylic dianhydride such as biphenyltetracarboxylic dianhydride (a-BPDA), oxydiphthalic dianhydride, diphenylsulfone-3,4,3 ', 4'-tetracarboxylic dianhydride, bis (3,4-dicarboxyphenyl) sulfide dianhydride, 2,2-bis (3,4-dicarboxyphenyl) -1,1,1,3,3,3-hexafluoropropane dianhydride, 2, 3,3 ′, 4′-benzophenone tetracarboxylic dianhydride, 3,3 ′, 4,4′-benzophenone tetracarboxylic dianhydride, bis (3,4-dicarboxyphenyl) methane dianhydride 2,2-bis (3,4-dicarboxyphenyl) propane dianhydride, p-phenylenebis (trimellitic acid monoester acid an
- At least one aromatic tetracarboxylic dianhydride selected from the group consisting of biphenyltetracarboxylic dianhydride and pyromellitic dianhydride is particularly preferable.
- the biphenyltetracarboxylic dianhydride 3,3 ′, 4,4′-biphenyltetracarboxylic dianhydride can be suitably used.
- Arbitrary diamine can be used for the diamine which can be used in manufacture of the said polyimide porous membrane.
- diamines include the following. 1) One benzene nucleus such as 1,4-diaminobenzene (paraphenylenediamine), 1,3-diaminobenzene, 2,4-diaminotoluene, 2,6-diaminotoluene, etc .; 2) 4,4'-diaminodiphenyl ether, diaminodiphenyl ether such as 3,4'-diaminodiphenyl ether, 4,4'-diaminodiphenylmethane, 3,3'-dimethyl-4,4'-diaminobiphenyl, 2,2'- Dimethyl-4,4′-diaminobiphenyl, 2,2′-bis (trifluoromethyl) -4,4′-diaminobiphenyl, 3,3′-dimethyl-4,4′-dia
- diamine to be used can be appropriately selected according to desired characteristics.
- aromatic diamine compounds are preferable, and 3,3′-diaminodiphenyl ether, 3,4′-diaminodiphenyl ether, 4,4′-diaminodiphenyl ether and paraphenylenediamine, 1,3-bis (3-aminophenyl) Benzene, 1,3-bis (4-aminophenyl) benzene, 1,4-bis (3-aminophenyl) benzene, 1,4-bis (4-aminophenyl) benzene, 1,3-bis (4-amino) Phenoxy) benzene and 1,4-bis (3-aminophenoxy) benzene can be preferably used.
- at least one diamine selected from the group consisting of benzenediamine, diaminodiphenyl ether and bis (aminophenoxy) phenyl is preferred.
- the polyimide porous membrane that can be used in the implant of the present invention has a glass transition temperature of 240 ° C. or higher or no clear transition point at 300 ° C. or higher from the viewpoint of heat resistance and dimensional stability at high temperatures. It is preferably formed from a polyimide obtained by combining tetracarboxylic dianhydride and diamine.
- the polyimide porous membrane that can be used in the implant of the present invention is preferably a polyimide porous membrane made of the following aromatic polyimide from the viewpoint of heat resistance and dimensional stability at high temperatures.
- an aromatic polyimide comprising at least one tetracarboxylic acid unit selected from the group consisting of a biphenyltetracarboxylic acid unit and a pyromellitic acid unit, and an aromatic diamine unit
- an aromatic polyimide comprising a tetracarboxylic acid unit and at least one aromatic diamine unit selected from the group consisting of a benzenediamine unit, a diaminodiphenyl ether unit and a bis (aminophenoxy) phenyl unit;
- the polyimide porous membrane used in the implant of the present invention preferably has a surface layer A and a surface layer B having a plurality of pores, and a macrovoid layer sandwiched between the surface layer A and the surface layer B.
- the macrovoid layer includes a partition wall coupled to the surface layers A and B, and a plurality of macrovoids surrounded by the partition wall and the surface layers A and B, and the partition wall of the macrovoid layer, and
- the thicknesses of the surface layers A and B are 0.01 to 20 ⁇ m
- the holes in the surface layers A and B communicate with the macrovoids
- the total film thickness is 5 to 500 ⁇ m
- the porosity is 40 % Or more 9 It is less than%
- a polyimide porous film at least one partition wall in the macrovoid layer has one or a plurality of holes having an average pore diameter of 0.01 to 100 ⁇ m, preferably 0.01 to 50 ⁇ m, which communicate adjacent macrovoids.
- polyimide porous membrane described in International Publication WO2010 / 038873, JP2011-219585, or JP2011-219586 can also be used for the implant of the present invention.
- the PES porous membrane that can be used in the present invention contains polyethersulfone, and is typically substantially composed of polyethersulfone.
- Polyethersulfone may be synthesized by a method known to those skilled in the art, for example, a method of polycondensation reaction of a dihydric phenol, an alkali metal compound and a dihalogenodiphenyl compound in an organic polar solvent, An alkali metal disalt can be synthesized in advance and can be produced by a polycondensation reaction with a dihalogenodiphenyl compound in an organic polar solvent.
- alkali metal compound examples include alkali metal carbonates, alkali metal hydroxides, alkali metal hydrides, alkali metal alkoxides, and the like.
- sodium carbonate and potassium carbonate are preferable.
- dihydric phenol compounds examples include hydroquinone, catechol, resorcin, 4,4′-biphenol, bis (hydroxyphenyl) alkanes (for example, 2,2-bis (hydroxyphenyl) propane, and 2,2-bis (hydroxyphenyl) Methane), dihydroxydiphenyl sulfones, dihydroxydiphenyl ethers, or at least one hydrogen of the benzene ring is a lower alkyl group such as a methyl group, an ethyl group or a propyl group, or a lower alkoxy group such as a methoxy group or an ethoxy group.
- the substituted one is mentioned.
- the dihydric phenol compound a mixture of two or more of the above compounds can be used.
- the polyethersulfone may be a commercially available product.
- a commercial item Sumika Excel 7600P, Sumika Excel 5900P (above, Sumitomo Chemical Co., Ltd. product) etc. are mentioned.
- the logarithmic viscosity of the polyethersulfone is preferably 0.5 or more, more preferably 0.55 or more, from the viewpoint of satisfactorily forming the macrovoids of the polyethersulfone porous membrane. From the viewpoint of ease, it is preferably 1.0 or less, more preferably 0.9 or less, still more preferably 0.8 or less, and particularly preferably 0.75 or less.
- the PES porous membrane or polyethersulfone as a raw material thereof has a glass transition temperature of 200 ° C. or higher or a clear glass transition temperature from the viewpoint of heat resistance and dimensional stability at high temperatures. Preferably it is not observed.
- the production method of the PES porous membrane that can be used in the present invention is not particularly limited.
- a polyethersulfone solution containing 0.3% to 60% by weight of polyethersulfone having a logarithmic viscosity of 0.5 to 1.0 and 40% to 99.7% by weight of an organic polar solvent is cast into a film.
- the PES porous membrane that can be used in the present invention preferably has a surface layer A, a surface layer B, and a macrovoid layer sandwiched between the surface layer A and the surface layer B. Because the macrovoid layer includes a partition bonded to the surface layers A and B, and a plurality of macrovoids surrounded by the partition and the surface layers A and B and having an average pore diameter of 10 ⁇ m to 500 ⁇ m in the film plane direction.
- the partition wall of the macrovoid layer has a thickness of 0.1 ⁇ m to 50 ⁇ m
- Each of the surface layers A and B has a thickness of 0.1 ⁇ m to 50 ⁇ m
- one has a plurality of pores having an average pore diameter of more than 5 ⁇ m and not more than 200 ⁇ m, and the other has a plurality of pores having an average pore diameter of 0.01 ⁇ m or more and less than 200 ⁇ m
- the surface opening ratio of one of the surface layer A and the surface layer B is 15% or more, and the surface opening ratio of the other surface layer is 10% or more
- the pores of the surface layer A and the surface layer B communicate with the macrovoid;
- the PES porous membrane has a total film thickness of 5 ⁇ m to 500 ⁇ m and a porosity of 50% to 95%. PES porous membrane.
- the “layer containing a biocompatible material” used in the implant of the present invention may be a layer made of a biocompatible material or a layer substantially made of a biocompatible material. In the case of a layer made of a biocompatible material, for example, the biocompatible material or impurities mixed during preparation of the layer may be included.
- the “layer containing a biocompatible material” used in the implant of the present invention may be a layer made of one biocompatible material (or a layer made substantially of a biocompatible material). A layer in which a layer made of a biocompatible material (or a layer made substantially of a biocompatible material) is laminated may be used.
- the thickness of the “layer containing the biocompatible material” is not particularly limited, but is, for example, 10 ⁇ m to 5 cm, and preferably 50 ⁇ m to 1 cm.
- Biocompatible materials used in the implants of the present invention include collagen, silicone, fibronectin, laminin, polylysine, polylactide, polyglycolide, polycaprolactone, polyhydroxybutyrate, polylactide-co-caprolactone, polycarbonate, biodegradable polyurethane, Examples include, but are not limited to, polyetheresters, polyesteramides, hydroxyapatite, complexes of collagen and ⁇ -TCP ( ⁇ -tricalcium phosphate), and combinations thereof. Collagen is preferable. Although it does not specifically limit as a layer containing collagen, For example, Teldermis (trademark) and telplug (trademark) (all are the Olympus Biomaterials Corporation make) may be used.
- the layer containing a biocompatible material may be disposed on the surface layer A of the polymer porous membrane or may be disposed on the surface layer B.
- the layer containing the biocompatible material is disposed on the surface layer A of the polymer porous membrane.
- a method of arranging a layer containing a biocompatible material on the surface layer of the polymer porous membrane a method known to those skilled in the art can be appropriately used. For example, it may be performed by applying a solution containing a biocompatible material and drying it.
- a layer containing a pre-formed biocompatible material may be fixed to the surface of the porous polymer membrane by, for example, thermocompression bonding. Further, after the surface of the polymer porous membrane is heated, a layer containing a biocompatible material formed in advance may be fused.
- the surface of the polymer porous membrane may be partially or wholly treated by a process that changes its physical properties.
- a process that changes its physical properties For example, alkali treatment and calcium treatment are mentioned.
- the process of alkali-treating the surface of the polymer porous membrane for example, by applying an alkaline substance such as sodium hydroxide or potassium hydroxide to the surface of the polymer porous membrane, the physical characteristics of the surface of the polymer porous membrane can be adjusted.
- an alkaline substance such as sodium hydroxide or potassium hydroxide
- a substance containing calcium such as calcium chloride, calcium phosphate, or calcium fluoride is applied to the surface of the polymer porous membrane, and the surface of the polymer porous membrane is physically treated.
- a substance containing calcium such as calcium chloride, calcium phosphate, or calcium fluoride is applied to the surface of the polymer porous membrane, and the surface of the polymer porous membrane is physically treated.
- the step of treating the surface of the polyimide porous membrane with calcium may be performed following the step of treating the surface of the porous polymer membrane with alkali.
- the cells of the implant of the present invention may be loaded beforehand.
- the porous polymer membrane used in the implant of the present invention has a feature that it can retain and grow cells in its inherent three-dimensional structure. It is also possible to promote the treatment of the bone damage site by supporting the cell according to the purpose on the implant of the present invention and applying it to the bone damage site.
- a mode including a step of seeding cells on a surface of the implant on which a layer containing a biocompatible material is disposed;
- An embodiment comprising steps; and (C) Wetting one or both surfaces of the implant with a cell culture medium or a sterilized liquid, Loading the wet implant with the cell suspension; and The cells in the cell suspension remain in the implant and the water is drained; A mode comprising the steps.
- the cells seeded on the surface of the implant of the present invention enter into the pores of the polymer porous membrane.
- Cells seeded on the surface of the implant of the present invention can stably grow and proliferate on the surface and / or inside of the implant. Cells can take a variety of different forms depending on the location of the membrane in which they grow and multiply.
- the cells may be applied from the A surface side or the B surface side of the polymer porous membrane.
- the cells are applied from the A side.
- the cells are applied from the surface on which the layer containing the biocompatible material of the implant of the present invention is disposed.
- the cells After seeding cells on the surface of the implant of the present invention, the cells may be cultured in the implant according to the purpose.
- the cultured cells are carried on the implant of the present invention.
- the type of cells to be carried on the implant of the present invention is not particularly limited, and any cell can be used, but generally cells derived from animals belonging to the class of mammals called mammals are preferably used. Mammals are not particularly limited, but preferably include mice, rats, humans, monkeys, pigs, dogs, sheep, goats and the like.
- the type of animal cell to be carried on the implant of the present invention is not limited, but is preferably selected from the group consisting of pluripotent stem cells, tissue stem cells, somatic cells, and combinations thereof.
- pluripotent stem cell is intended to be a generic term for stem cells having the ability to differentiate into cells of any tissue (differentiated pluripotency).
- the pluripotent stem cells include, but are not limited to, embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), embryonic germ stem cells (EG cells), germ stem cells (GS cells), and the like. .
- ES cells embryonic stem cells
- iPS cells induced pluripotent stem cells
- EG cells embryonic germ stem cells
- GS cells germ stem cells
- Any known pluripotent stem cell can be used.
- the pluripotent stem cell described in International Publication WO2009 / 123349 PCT / JP2009 / 057041
- PCT / JP2009 / 057041 can be used.
- tissue stem cell means a stem cell that has the ability to differentiate into various cell types (differentiated pluripotency) although the cell line that can be differentiated is limited to a specific tissue.
- hematopoietic stem cells in the bone marrow become blood cells, and neural stem cells differentiate into nerve cells.
- the tissue stem cells are selected from mesenchymal stem cells, hepatic stem cells, pancreatic stem cells, neural stem cells, skin stem cells, or hematopoietic stem cells.
- somatic cell refers to a cell other than a germ cell among cells constituting a multicellular organism. In sexual reproduction, it is not passed on to the next generation.
- the somatic cells are hepatocytes, pancreatic cells, muscle cells, bone cells, osteoblasts, osteoclasts, chondrocytes, adipocytes, skin cells, fibroblasts, pancreatic cells, kidney cells, lung cells, or , Lymphocytes, erythrocytes, leukocytes, monocytes, macrophages or megakaryocyte blood cells.
- germ cell means a cell having a role of transmitting genetic information to the next generation in reproduction. For example, gametes for sexual reproduction, ie eggs, egg cells, sperm, sperm cells, spores for asexual reproduction, and the like.
- the cells may be selected from the group consisting of sarcoma cells, established cells, and transformed cells.
- “Sarcoma” is a cancer that develops in connective tissue cells derived from non-epithelial cells such as bone, cartilage, fat, muscle, blood, etc., and includes soft tissue sarcoma, malignant bone tumor and the like.
- Sarcoma cells are cells derived from sarcomas.
- the “established cell” means a cultured cell that has been maintained outside the body for a long period of time, has a certain stable property, and is capable of semi-permanent subculture.
- PC12 cells derived from rat adrenal medulla
- CHO cells derived from Chinese hamster ovary
- HEK293 cells derived from human fetal kidney
- HL-60 cells derived from human leukocyte cells
- HeLa cells derived from human cervical cancer
- Vero cells There are cell lines derived from various tissues of various biological species including humans (derived from African green monkey kidney epithelial cells), MDCK cells (derived from canine kidney tubular epithelial cells), HepG2 cells (derived from human liver cancer).
- a “transformed cell” means a cell in which a nucleic acid (DNA or the like) has been introduced from the outside of the cell to change its genetic properties. Appropriate methods are known for transformation of animal cells, plant cells, and bacteria.
- the cells to be carried on the implant of the present invention include bone marrow cells, mesenchymal stem cells, osteoblasts and fibroblasts.
- the bone marrow cells may be cells collected from mammalian bone marrow.
- Bone marrow cells can be collected from the bone marrow using a known method such as bone marrow puncture or bone marrow flushing.
- the bone marrow cells may also be primary cultured cells collected from mammalian bone marrow.
- the porous polymer membrane used in the implant of the present invention has an inherent three-dimensional structure that is similar in shape to the bone marrow structure (see, for example, FIG. 1).
- the present inventors can proliferate CD45 positive cells by seeding and culturing bone marrow cells on the polymer porous membrane, and have differentiation characteristics similar to bone marrow according to the three-dimensional structure of the polymer porous membrane. It was found that a cell mass was formed.
- the implant of the present invention may be one obtained by seeding and culturing bone marrow cells. A well-known thing can be used suitably for the culture medium for culture
- the implant of the present invention may be an implant carrying bone marrow cells collected from a bone injury treatment target.
- an implant for bone injury treatment it is possible to restore not only structural complementation of the bone injury site but also bone function including hematopoiesis.
- a method for supporting cells on the implant of the present invention for example, a method including the following steps can be used. (1) applying and culturing the first cell group to the implant; and (2) applying, culturing and supporting the second cell group to the implant after culturing in step (1), wherein The second cell group is bone marrow cells.
- the type of the first cell group may be any cell, for example, selected from the group consisting of animal cells, insect cells, plant cells, yeasts and bacteria. Good. Animal cells are roughly classified into cells derived from animals belonging to the vertebrate phylum and cells derived from invertebrates (animals other than animals belonging to the vertebrate phylum).
- the first cell group is preferably bone marrow cells.
- the implant of the present invention further includes a metal mesh.
- the metal mesh is included, the layer containing the biocompatible material, the polymer porous membrane, and the metal mesh are arranged in this order in the implant of the present invention.
- the “metal mesh” is composed of a metal component and has a large number of through holes in a sheet-like surface, and is not particularly limited as long as it satisfies such requirements.
- a metal mesh By using a metal mesh, the mechanical strength of the implant of the present invention can be improved, and a stable field for bone healing is created.
- the metal mesh also helps to maintain the shape of the implant in a fixed position.
- the metal mesh may be secured to the polymeric porous membrane with any securing means (eg, sutures, staples, biocompatible screws, etc.).
- the metal mesh is not particularly limited, and may be composed of, for example, titanium, stainless steel, titanium-coated steel, titanium nitride, or a combination thereof.
- the implant of the present invention is rich in flexibility and excellent in the degree of freedom of shape, it can be used by cutting, molding, or processing into an arbitrary shape according to the state of the affected part of the bone injury.
- the implant of the present invention is transplanted in vivo so as to be in contact with the affected area of bone damage.
- the implant of the present invention may be in contact with the entire bone injury affected area, or the polyimide porous membrane may be in contact with a part of the bone injury affected area.
- the implant of the present invention is preferably used by implanting it in the living body so that the surface on which the layer containing the biocompatible material is disposed is in contact with the affected part of the bone injury.
- the implant of the present invention can also be used effectively for the treatment of a large bone defect site or a complicated fracture site, which was impossible with conventional techniques.
- the implant of the present invention may be applied so as to cover the whole or part of the affected part of the bone damage, and it is not particularly necessary to fix the implant using another material. However, it may be fixed to the living tissue using a fixing means such as a suture, a staple, or a biocompatible screw depending on the purpose.
- One aspect of the present invention relates to a bone injury treatment kit including the implant of the present invention, materials necessary for bone injury treatment surgery, and an instruction manual.
- a package containing a form of the implant of the present invention sterilized in a transparent pouch, which is singly or plurally stored and can be used as it is for bone injury treatment, or
- a sterilizing liquid is enclosed together with the implant of the present invention, and the kit includes an integrated membrane / liquid kit that enables efficient cell seeding.
- the material necessary for the treatment operation is not particularly limited, and may include, for example, a fixing means (for example, a suture thread, a staple or a biocompatible screw) for fixing the implant of the present invention to the affected part of the bone damage. good.
- a fixing means for example, a suture thread, a staple or a biocompatible screw
- One aspect of the present invention relates to a method for treating a bone injury site, which includes applying the implant of the present invention to the bone injury site.
- the polyimide porous membrane used in the following examples is composed of 3,3 ′, 4,4′-biphenyltetracarboxylic dianhydride (s-BPDA) which is a tetracarboxylic acid component and 4,4 which is a diamine component. It was prepared by molding a polyamic acid solution composition containing a polyamic acid solution obtained from '-diaminodiphenyl ether (ODA) and a polyacrylamide as a coloring precursor, and then heat-treating it at 250 ° C. or higher.
- s-BPDA 4,4′-biphenyltetracarboxylic dianhydride
- the obtained polyimide porous film is a three-layer polyimide porous film having a surface layer A and a surface layer B having a plurality of pores, and a macrovoid layer sandwiched between the surface layer A and the surface layer B.
- the average pore size of the pores existing in the surface layer A was 6 ⁇ m
- the average pore size of the pores existing in the surface layer B was 46 ⁇ m
- the film thickness was 25 ⁇ m
- the porosity was 73%.
- Example 1 A 9-week-old LEW rat is anesthetized with 2-3% isoflurane and then subjected to infiltration anesthesia with 1 / 10,000 epinephrine-containing lidocaine. After removing the hair over a wider area than the incision, an incision is made in a straight line up to the subperiosteum at the top of the head so that the surgical field can be clearly shown. After exfoliating the skin periosteal flap and exposing the parietal bone, two 4 mm diameter circular bone defects were formed under water injection with sterile saline using a trephine bar.
- the skin periosteal flap was repositioned and sutured with a nylon thread.
- a model prepared by grounding the mesh surface (A surface) of the polyimide porous membrane to the wound portion and a model prepared by grounding the large hole surface (B surface) were prepared.
- the healing state of the defect was measured after 2 weeks, 4 weeks, and 8 weeks.
- the measurement items are bone density (BMD) (mg / cm 3 ), bone mineral content (BMC) (mg), new bone volume (BV) (cm 3 ), set ROI volume (TV) (cm 3 ), Percentage of new bone (BV / TV) (%), clinical BMD (BMC / TV) (mg / cm 3 ).
- BMD bone density
- BMC bone mineral content
- BV new bone volume
- TV ROI volume
- Percentage of new bone BV / TV
- FIG. 4 the control group is a group in which the bone defect portion was not covered with the polyimide porous membrane.
- Example 2 A femur and a tibia were collected from an 8-week-old GFP transgenic rat, both ends of each bone were cut, and the bone marrow cell sputum was collected by flushing with DMEM medium supplemented with 10% FBS.
- the cell mass is pulverized by pipetting, and 1.0 ⁇ 10 6 bone marrow cells are seeded on the mesh surface (A surface) of a 1.5 cm square polyimide porous membrane, and 5 days in DMEM medium supplemented with 10% FBS.
- the culture was stationary. On the sixth day, the polyimide porous membrane to which the cells adhered was washed with a phosphate buffer, and the medium was changed to only DMEM, followed by further culturing for one day.
- the defect portion was covered with a polyimide porous membrane that was adhered and then cultured so that the mesh surface (A surface) was in contact with the wound portion at the defect portion. After 2 weeks, 4 weeks, and 8 weeks, the healing state of the defect was measured to confirm the healing of the wound over time. The results are shown in FIG.
- Example 3 A femur and a tibia were collected from an 8-week-old GFP transgenic rat, both ends of each bone were cut, and the bone marrow cell sputum was collected by flushing with DMEM medium supplemented with 10% FBS.
- the cell mass is pulverized by pipetting, and 1.0 ⁇ 10 6 bone marrow cells are seeded on the mesh surface (A surface) of a 1.5 cm square polyimide porous membrane, and 5 days in DMEM medium supplemented with 10% FBS.
- the culture was stationary. After changing the DMEM medium, the cells were further cultured for 1 day.
- an incision is made in a straight line up to the subperiosteum at the top of the head so that the surgical field can be clearly shown.
- two 4 mm diameter circular bone defects were formed under water injection with sterile saline using a trephine bar.
- the defect portion was covered with a polyimide porous membrane that was adhered and then cultured so that the mesh surface (A surface) was in contact with the wound portion at the defect portion.
- the healing state of the defect was measured to confirm the healing of the wound over time. The results are shown in FIGS.
- Example 4 Compounding of Polyimide Porous Membrane and Teldermis (Registered Trademark)
- the Teldermis (Registered Trademark) dermal defect graft (Alcare) was opened aseptically and cut into scissors to the same size as the polyimide porous membrane to be tested.
- a polyimide porous film was placed on the upper surface (silicone layer side) of Teldermis (registered trademark), and fused to the silicone layer with tweezers heated with a flame.
- Example 5 Time-dependent change in cell number when osteoblasts are cultured on Teldermis (registered trademark) and on a composite material of polyimide porous membrane and Teldermis (registered trademark)
- the polyimide porous membrane produced in Example 4 and Teldermis The composite with (registered trademark) (sterilized, 1.4 cm square) was placed in a 2 cm ⁇ 2 cm sterilized square container (Thermo Fisher Scientific cat. 103). 4 ⁇ 10 4 cells were seeded, 4 ml of osteoblast growth medium was added, and the culture was continuously performed in a CO 2 incubator while changing the medium twice a week.
- the implant of the present invention can easily and effectively treat bone damage including a large defect site or a complex shape site.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Description
骨折及び骨欠損を含む骨損傷の治癒は、患者QOLの観点から、古くより、プレートやスクリューで患部を固定するなどの方法により、数多くの器具や手段を用いる術式等が試みられている。近年、様々な構造的特長・機能的特長・生体親和的特長を備えた骨疾患治癒素材や器具が創製され、医療に利用されている(非特許文献1、特許文献1)。例えばチタンメッシュは高い堅牢性、柔軟性及び生活適合性を兼ね備えた特性により、多くの骨損傷や口腔内疾患治療等に使用されている。チタンメッシュは安定した創傷治癒空間を付与し得るが、それ自体に骨損傷治癒効果があるわけではない。
ポリイミド多孔質膜は、本出願前よりフィルター、低誘電率フィルム、燃料電池用電解質膜など、特に電池関係を中心とする用途のために利用されてきた。特許文献4~6は、特に、気体などの物質透過性に優れ、空孔率の高い、両表面の平滑性が優れ、相対的に強度が高く、高空孔率にもかかわらず、膜厚み方向への圧縮応力に対する耐力に優れるマクロボイドを多数有するポリイミド多孔質膜を記載している。これらはいずれも、アミック酸を経由して作成されたポリイミド多孔質膜である。
[1]
ポリマー多孔質膜と、生体適合性材料を含む層とを含む、骨損傷部位の治療のためのインプラントであって、前記ポリマー多孔質膜が、複数の孔を有する表面層A及び表面層Bと、前記表面層A及び表面層Bの間に挟まれたマクロボイド層とを有する三層構造のポリマー多孔質膜であり、ここで前記表面層Aに存在する孔の平均孔径は、前記表面層Bに存在する孔の平均孔径よりも小さく、前記マクロボイド層は、前記表面層A及びBに結合した隔壁と、当該隔壁並びに前記表面層A及びBに囲まれた複数のマクロボイドとを有し、前記表面層A及びBにおける孔が前記マクロボイドに連通している、前記インプラント。
[2]
前記生体適合性材料を含む層が、前記ポリマー多孔質膜の表面層A上に配置される、[1]に記載のインプラント。
[3]
前記生体適合性材料が、コラーゲン、シリコーン、フィブロネクチン、ラミニン、ポリリジン、ポリラクチド、ポリグリコリド、ポリカプロラクトン、ポリヒドロキシブチレート、ポリラクチド-コ-カプロラクトン、ポリカーボネート、生体分解性ポリウレタン、ポリエーテルエステル、ポリエステルアミド、ヒドロキシアパタイト、コラーゲンとβ-TCPとの複合体及びこれらの組み合わせからなる群から選択される化合物である、[1]又は[2]に記載のインプラント。
[4]
前記生体適合性材料がコラーゲンである、[1]~[3]のいずれか1つに記載のインプラント。
[5]
前記表面層Aの平均孔径が、0.01~50μmである、[1]~[4]のいずれか1つに記載のインプラント。
[6]
前記表面層Bの平均孔径が、20~100μmである、[1]~[5]のいずれか1つに記載のインプラント。
[7]
前記ポリマー多孔質膜の膜厚が、5~500μmである、[1]~[6]のいずれか1つに記載のインプラント。
[8]
前記ポリマー多孔質膜がポリイミド多孔質膜である、[1]~[7]のいずれか1つに記載のインプラント。
[9]
ポリイミド多孔質膜が、テトラカルボン酸二無水物とジアミンとから得られるポリイミドを含む、ポリイミド多孔質膜である、[8]に記載のインプラント。
[10]
ポリイミド多孔質膜が、テトラカルボン酸二無水物とジアミンとから得られるポリアミック酸溶液と着色前駆体とを含むポリアミック酸溶液組成物を成形した後、250℃以上で熱処理することにより得られる着色したポリイミド多孔質膜である、[8]又は[9]に記載のインプラント。
[11]
前記ポリマー多孔質膜が、ポリエーテルスルホン多孔質膜である、[1]~[7]のいずれか1つに記載のインプラント。
[12]
細胞が担持されている、[1]~[11]のいずれか1つに記載のインプラント。
[13]
前記細胞が、骨髄細胞、間葉系幹細胞、線維芽細胞、骨芽細胞、又はこれらから誘導された細胞である、[12]に記載のインプラント。
[14]
金属メッシュをさらに含み、生体適合性材料を含む層、ポリマー多孔質膜及び金属メッシュがこの順に配置される、[1]~[13]のいずれか1つに記載のインプラント。
[15]
前記金属メッシュが、チタン、ステンレス鋼、チタンコーティングされた鋼、窒化チタン又はそれらの組み合わせで構成される、[14]に記載のインプラント。
[16]
[1]~[15]のいずれか1つに記載のインプラント、
骨損傷治療手術に必要な材料、及び
取扱説明書
を含む、骨損傷治療用キット。
[17]
[1]~[15]のいずれか1つに記載のインプラントを骨損傷部位に適用することを含む、骨損傷部位の治療方法。
1)1,4-ジアミノベンゼン(パラフェニレンジアミン)、1,3-ジアミノベンゼン、2,4-ジアミノトルエン、2,6-ジアミノトルエンなどのベンゼン核1つのべンゼンジアミン;
2)4,4’-ジアミノジフェニルエーテル、3,4’-ジアミノジフェニルエーテルなどのジアミノジフェニルエーテル、4,4’-ジアミノジフェニルメタン、3,3’-ジメチル-4,4’-ジアミノビフェニル、2,2’-ジメチル-4,4’-ジアミノビフェニル、2,2’-ビス(トリフルオロメチル)-4,4’-ジアミノビフェニル、3,3’-ジメチル-4,4’-ジアミノジフェニルメタン、3,3’-ジカルボキシ-4,4’-ジアミノジフェニルメタン、3,3’,5,5’-テトラメチル-4,4’-ジアミノジフェニルメタン、ビス(4-アミノフェニル)スルフィド、4,4’-ジアミノベンズアニリド、3,3’-ジクロロベンジジン、3,3’-ジメチルベンジジン、2,2’-ジメチルベンジジン、3,3’-ジメトキシベンジジン、2,2’-ジメトキシベンジジン、3,3’-ジアミノジフェニルエーテル、3,4’-ジアミノジフェニルエーテル、4,4’-ジアミノジフェニルエーテル、3,3’-ジアミノジフェニルスルフィド、3,4’-ジアミノジフェニルスルフィド、4,4’-ジアミノジフェニルスルフィド、3,3’-ジアミノジフェニルスルホン、3,4’-ジアミノジフェニルスルホン、4,4’-ジアミノジフェニルスルホン、3,3’-ジアミノベンゾフェノン、3,3’-ジアミノ-4,4’-ジクロロベンゾフェノン、3,3’-ジアミノ-4,4’-ジメトキシベンゾフェノン、3,3’-ジアミノジフェニルメタン、3,4’-ジアミノジフェニルメタン、4,4’-ジアミノジフェニルメタン、2,2-ビス(3-アミノフェニル)プロパン、2,2-ビス(4-アミノフェニル)プロパン、2,2-ビス(3-アミノフェニル)-1,1,1,3,3,3-ヘキサフルオロプロパン、2,2-ビス(4-アミノフェニル)-1,1,1,3,3,3-ヘキサフルオロプロパン、3,3’-ジアミノジフェニルスルホキシド、3,4’-ジアミノジフェニルスルホキシド、4,4’-ジアミノジフェニルスルホキシドなどのベンゼン核2つのジアミン;
3)1,3-ビス(3-アミノフェニル)ベンゼン、1,3-ビス(4-アミノフェニル)ベンゼン、1,4-ビス(3-アミノフェニル)ベンゼン、1,4-ビス(4-アミノフェニル)ベンゼン、1,3-ビス(4-アミノフェノキシ)ベンゼン、1,4-ビス(3-アミノフェノキシ)ベンゼン、1,4-ビス(4-アミノフェノキシ)ベンゼン、1,3-ビス(3-アミノフェノキシ)-4-トリフルオロメチルベンゼン、3,3’-ジアミノ-4-(4-フェニル)フェノキシベンゾフェノン、3,3’-ジアミノ-4,4’-ジ(4-フェニルフェノキシ)ベンゾフェノン、1,3-ビス(3-アミノフェニルスルフィド)ベンゼン、1,3-ビス(4-アミノフェニルスルフィド)ベンゼン、1,4-ビス(4-アミノフェニルスルフィド)ベンゼン、1,3-ビス(3-アミノフェニルスルホン)ベンゼン、1,3-ビス(4-アミノフェニルスルホン)ベンゼン、1,4-ビス(4-アミノフェニルスルホン)ベンゼン、1,3-ビス〔2-(4-アミノフェニル)イソプロピル〕ベンゼン、1,4-ビス〔2-(3-アミノフェニル)イソプロピル〕ベンゼン、1,4-ビス〔2-(4-アミノフェニル)イソプロピル〕ベンゼンなどのベンゼン核3つのジアミン;
4)3,3’-ビス(3-アミノフェノキシ)ビフェニル、3,3’-ビス(4-アミノフェノキシ)ビフェニル、4,4’-ビス(3-アミノフェノキシ)ビフェニル、4,4’-ビス(4-アミノフェノキシ)ビフェニル、ビス〔3-(3-アミノフェノキシ)フェニル〕エーテル、ビス〔3-(4-アミノフェノキシ)フェニル〕エーテル、ビス〔4-(3-アミノフェノキシ)フェニル〕エーテル、ビス〔4-(4-アミノフェノキシ)フェニル〕エーテル、ビス〔3-(3-アミノフェノキシ)フェニル〕ケトン、ビス〔3-(4-アミノフェノキシ)フェニル〕ケトン、ビス〔4-(3-アミノフェノキシ)フェニル〕ケトン、ビス〔4-(4-アミノフェノキシ)フェニル〕ケトン、ビス〔3-(3-アミノフェノキシ)フェニル〕スルフィド、ビス〔3-(4-アミノフェノキシ)フェニル〕スルフィド、ビス〔4-(3-アミノフェノキシ)フェニル〕スルフィド、ビス〔4-(4-アミノフェノキシ)フェニル〕スルフィド、ビス〔3-(3-アミノフェノキシ)フェニル〕スルホン、ビス〔3-(4-アミノフェノキシ)フェニル〕スルホン、ビス〔4-(3-アミノフェノキシ)フェニル〕スルホン、ビス〔4-(4-アミノフェノキシ)フェニル〕スルホン、ビス〔3-(3-アミノフェノキシ)フェニル〕メタン、ビス〔3-(4-アミノフェノキシ)フェニル〕メタン、ビス〔4-(3-アミノフェノキシ)フェニル〕メタン、ビス〔4-(4-アミノフェノキシ)フェニル〕メタン、2,2-ビス〔3-(3-アミノフェノキシ)フェニル〕プロパン、2,2-ビス〔3-(4-アミノフェノキシ)フェニル〕プロパン、2,2-ビス〔4-(3-アミノフェノキシ)フェニル〕プロパン、2,2-ビス〔4-(4-アミノフェノキシ)フェニル〕プロパン、2,2-ビス〔3-(3-アミノフェノキシ)フェニル〕-1,1,1,3,3,3-ヘキサフルオロプロパン、2,2-ビス〔3-(4-アミノフェノキシ)フェニル〕-1,1,1,3,3,3-ヘキサフルオロプロパン、2,2-ビス〔4-(3-アミノフェノキシ)フェニル〕-1,1,1,3,3,3-ヘキサフルオロプロパン、2,2-ビス〔4-(4-アミノフェノキシ)フェニル〕-1,1,1,3,3,3-ヘキサフルオロプロパンなどのベンゼン核4つのジアミン。
(i)ビフェニルテトラカルボン酸単位及びピロメリット酸単位からなる群から選ばれる少なくとも一種のテトラカルボン酸単位と、芳香族ジアミン単位とからなる芳香族ポリイミド、
(ii)テトラカルボン酸単位と、ベンゼンジアミン単位、ジアミノジフェニルエーテル単位及びビス(アミノフェノキシ)フェニル単位からなる群から選ばれる少なくとも一種の芳香族ジアミン単位とからなる芳香族ポリイミド、
及び/又は、
(iii)ビフェニルテトラカルボン酸単位及びピロメリット酸単位からなる群から選ばれる少なくとも一種のテトラカルボン酸単位と、ベンゼンジアミン単位、ジアミノジフェニルエーテル単位及びビス(アミノフェノキシ)フェニル単位からなる群から選ばれる少なくとも一種の芳香族ジアミン単位とからなる芳香族ポリイミド。
対数粘度0.5~1.0のポリエーテルスルホンの0.3質量%~60質量%と有機極性溶媒40質量%~99.7質量%とを含むポリエーテルスルホン溶液を、フィルム状に流延し、ポリエーテルスルホンの貧溶媒又は非溶媒を必須成分とする凝固溶媒に浸漬又は接触させて、空孔を有する凝固膜を作製する工程、及び
前記工程で得られた空孔を有する凝固膜を熱処理して前記空孔を粗大化させて、PES多孔質膜を得る工程
を含み、前記熱処理は、前記空孔を有する凝固膜を、前記ポリエーテルスルホンのガラス転移温度以上、若しくは240℃以上まで昇温させることを含む、方法で製造されてもよい。
前記マクロボイド層は、前記表面層A及びBに結合した隔壁と、当該隔壁並びに前記表面層A及びBに囲まれた、膜平面方向の平均孔径が10μm~500μmである複数のマクロボイドとを有し、
前記マクロボイド層の隔壁は、厚さが0.1μm~50μmであり、
前記表面層A及びBはそれぞれ、厚さが0.1μm~50μmであり、
前記表面層A及びBのうち、一方が平均孔径5μm超200μm以下の複数の細孔を有し、かつ他方が平均孔径0.01μm以上200μm未満の複数の細孔を有し、
表面層A及び表面層Bの、一方の表面開口率が15%以上であり、他方の表面層の表面開口率が10%以上であり、
前記表面層A及び前記表面層Bの前記細孔が前記マクロボイドに連通しており、
前記PES多孔質膜は、総膜厚が5μm~500μmであり、かつ空孔率が50%~95%である、
PES多孔質膜である。
(A)前記インプラント中の、生体適合性材料を含む層が配置された面に、細胞を播種する工程を含む、態様;
(B)前記インプラント中の、生体適合性材料を含む層が配置された面に細胞懸濁液を載せ、
放置するか、あるいは前記インプラントを移動して液の流出を促進するか、あるいは表面の一部を刺激して、細胞懸濁液を前記インプラントのポリマー多孔質膜に吸い込ませ、そして、
細胞懸濁液中の細胞を前記ポリマー多孔質膜内に留め、水分は流出させる、
工程を含む、態様;並びに、
(C)前記インプラントの片面又は両面を、細胞培養液又は滅菌された液体で湿潤し、
湿潤したインプラントに細胞懸濁液を装填し、そして、
細胞懸濁液中の細胞を前記インプラント内に留め、水分は流出させる、
工程を含む、態様。
(D)創傷部もしくは欠損部にインプラントを埋め込み、直接骨髄液を掛ける工程を含む、態様。
(1)第一の細胞群をインプラントに適用し、培養する工程、及び
(2)工程(1)の培養後のインプラントに第二の細胞群を適用し、培養し、担持させる工程、ここで第二の細胞群は骨髄細胞である。
9週齢のLEWラットを2~3%イソフルレンにて全身麻酔後、術野に1万分の1エピネフリン含有リドカインによる浸潤麻酔を施す。切開部より広い範囲を除毛した後、術野が十分明示できるよう頭頂部に骨膜下まで直線上に切開を加える。皮膚骨膜弁を剥離し頭頂骨を露出した後、トレフィンバーを用い滅菌生理食塩水による注水下に4mm径円形の骨欠損部を2個形成した。欠損部を滅菌したポリイミド多孔質膜で被覆した後、皮膚骨膜弁を復位し、ナイロン糸にて縫合した。この際、ポリイミド多孔質膜のメッシュ面(A面)を創部に接地させて作製したモデルと大穴面(B面)を接地させたモデルをそれぞれ作製した。2週間後、4週間後、8週間後に欠損部の治癒状況を測定した。測定項目は、骨密度(BMD)(mg/cm3)、骨塩量(BMC)(mg)、新生骨体積(BV)(cm3)、設定したROIの体積(TV)(cm3)、新生骨の割合(BV/TV)(%)、臨床的なBMD(BMC/TV)(mg/cm3)である。メッシュ面接地のモデルにて、早期の骨形成に関し、メッシュ面を創部に接地したモデルが有意に骨形成を促進する結果が確認された。結果を図4に示す。図4において、コントロール群とは骨欠損部をポリイミド多孔質膜で被覆しなかった群のことである。
8週齢のGFP transgenic ratより大腿骨および頸骨を採取し、それぞれの骨の両端をカットして、FBSを10%添加したDMEM培地でフラッシュすることで骨髄細胞隗を採取した。細胞塊をピペテッィングにより粉砕し、1.5cm四方のポリイミド多孔質膜のメッシュ面(A面)に1.0×106個の骨髄細胞を播種し、10%FBSを添加したDMEM培地で5日間静置培養した。6日目に、細胞が付着したポリイミド多孔質膜を燐酸バッファーで洗浄し、培地をDMEMのみに変更して更に1日間培養した。9週齢のヌードラットを2~3%イソフルレンにて全身麻酔後、術野に1万分の1エピネフリン含有リドカインによる浸潤麻酔を施す。切開部より広い範囲を除毛した後、術野が十分明示できるよう頭頂部に骨膜下まで直線上に切開を加える。皮膚骨膜弁を剥離し頭頂骨を露出した後、トレフィンバーを用い滅菌生理食塩水による注水下に4mm径円形の骨欠損部を2個形成した。欠損部に、メッシュ面(A面)が創部に接地する様にして、上記の細胞を付着させその後培養したポリイミド多孔質膜にて欠損部を被覆した。2週、4週、8週後に欠損部治癒状況を測定し、経時的な創部の治癒を確認した。結果を図5に示す。
8週齢のGFP transgenic ratより大腿骨および頸骨を採取し、それぞれの骨の両端をカットして、FBSを10%添加したDMEM培地でフラッシュすることで骨髄細胞隗を採取した。細胞塊をピペテッィングにより粉砕し、1.5cm四方のポリイミド多孔質膜のメッシュ面(A面)に1.0×106個の骨髄細胞を播種し、10%FBSを添加したDMEM培地で5日間静置培養した。DMEM培地を交換した後、更に1日間培養した。その後、ポリイミド多孔質膜のメッシュ面(A面)に1.0×106個の骨髄細胞を播種し、10%FBSを添加したDMEM培地で5日間静置培養した。6日目に、細胞が付着したポリイミド多孔質膜を燐酸バッファーで洗浄し、培地をDMEMのみに変更して更に1日間培養した。得られたポリイミド多孔質膜を、9週齢のヌードラットを2~3%イソフルレンにて全身麻酔後、術野に1万分の1エピネフリン含有リドカインによる浸潤麻酔を施す。切開部より広い範囲を除毛した後、術野が十分明示できるよう頭頂部に骨膜下まで直線上に切開を加える。皮膚骨膜弁を剥離し頭頂骨を露出した後、トレフィンバーを用い滅菌生理食塩水による注水下に4mm径円形の骨欠損部を2個形成した。欠損部に、メッシュ面(A面)が創部に接地する様にして、上記の細胞を付着させその後培養したポリイミド多孔質膜にて欠損部を被覆した。2週、4週、8週後に欠損部治癒状況を測定し、経時的な創部の治癒を確認した。結果を図6~8に示す。
ポリイミド多孔質膜とテルダーミス(登録商標)との複合化
テルダーミス(登録商標)真皮欠損用グラフト(アルケア社)を滅菌的に開封し、試験するポリイミド多孔質膜と同サイズにハサミで切り出した。テルダーミス(登録商標)の上面(シリコーン層側)にポリイミド多孔質膜を置き、炎にて加熱したピンセットでシリコーン層に融着させた。
骨芽細胞をテルダーミス(登録商標)上、及びポリイミド多孔質膜とテルダーミス(登録商標)との複合材上で培養した場合における、細胞数の経時変化
実施例4で製造したポリイミド多孔質膜とテルダーミス(登録商標)との複合材(滅菌済み、1.4cm角の正方形)を、2cm×2cmの滅菌された正方形容器(Thermo Fisher Scientific 社 cat. 103)に入れた。4×104個の細胞を播種し骨芽細胞増殖培地4mlを加え、週2回培地を交換しながらCO2インキュベータ内で培養を継続的に行った。また、2.5cm×2.5cmテルダーミス(登録商標)を20cm2シャーレに入れ、同様の条件で骨芽細胞の播種と培養を実施した。播種後、3日、7日、14日、21日、28日、35日後、テルダーミスは9日、14日、21日、28日、35日後に、CCK8を用いて細胞数を計測し、増殖挙動を観察した。結果を図9に示す。培養期間中、テルダーミス(登録商標)上では殆ど細胞が増殖せず、また、移動する様子も観察されなかったが、ポリイミド多孔質膜を共存させるだけで、全培養期間を通じて細胞数の上昇が観察された。
Claims (17)
- ポリマー多孔質膜と、生体適合性材料を含む層とを含む、骨損傷部位の治療のためのインプラントであって、前記ポリマー多孔質膜が、複数の孔を有する表面層A及び表面層Bと、前記表面層A及び表面層Bの間に挟まれたマクロボイド層とを有する三層構造のポリマー多孔質膜であり、ここで前記表面層Aに存在する孔の平均孔径は、前記表面層Bに存在する孔の平均孔径よりも小さく、前記マクロボイド層は、前記表面層A及びBに結合した隔壁と、当該隔壁並びに前記表面層A及びBに囲まれた複数のマクロボイドとを有し、前記表面層A及びBにおける孔が前記マクロボイドに連通している、前記インプラント。
- 前記生体適合性材料を含む層が、前記ポリマー多孔質膜の表面層A上に配置される、請求項1に記載のインプラント。
- 前記生体適合性材料が、コラーゲン、シリコーン、フィブロネクチン、ラミニン、ポリリジン、ポリラクチド、ポリグリコリド、ポリカプロラクトン、ポリヒドロキシブチレート、ポリラクチド-コ-カプロラクトン、ポリカーボネート、生体分解性ポリウレタン、ポリエーテルエステル、ポリエステルアミド、ヒドロキシアパタイト、コラーゲンとβ-TCPとの複合体及びこれらの組み合わせからなる群から選択される化合物である、請求項1又は2のいずれか1項に記載のインプラント。
- 前記生体適合性材料がコラーゲンである、請求項1~3のいずれか1項に記載のインプラント。
- 前記表面層Aの平均孔径が、0.01~50μmである、請求項1~4のいずれか1項に記載のインプラント。
- 前記表面層Bの平均孔径が、20~100μmである、請求項1~5のいずれか1項に記載のインプラント。
- 前記ポリマー多孔質膜の膜厚が、5~500μmである、請求項1~6のいずれか1項に記載のインプラント。
- 前記ポリマー多孔質膜がポリイミド多孔質膜である、請求項1~7のいずれか1項に記載のインプラント。
- ポリイミド多孔質膜が、テトラカルボン酸二無水物とジアミンとから得られるポリイミドを含む、ポリイミド多孔質膜である、請求項8に記載のインプラント。
- ポリイミド多孔質膜が、テトラカルボン酸二無水物とジアミンとから得られるポリアミック酸溶液と着色前駆体とを含むポリアミック酸溶液組成物を成形した後、250℃以上で熱処理することにより得られる着色したポリイミド多孔質膜である、請求項8又は9に記載のインプラント。
- 前記ポリマー多孔質膜が、ポリエーテルスルホン多孔質膜である、請求項1~7のいずれか1項に記載のインプラント。
- 細胞が担持されている、請求項1~11のいずれか1項に記載のインプラント。
- 前記細胞が、骨髄細胞、間葉系幹細胞、線維芽細胞、骨芽細胞、又はこれらから誘導された細胞である、請求項12に記載のインプラント。
- 金属メッシュをさらに含み、生体適合性材料を含む層、ポリマー多孔質膜及び金属メッシュがこの順に配置される、請求項1~13のいずれか1項に記載のインプラント。
- 前記金属メッシュが、チタン、ステンレス鋼、チタンコーティングされた鋼、窒化チタン又はそれらの組み合わせで構成される、請求項14に記載のインプラント。
- 請求項1~15のいずれか1項に記載のインプラント、
骨損傷治療手術に必要な材料、及び
取扱説明書
を含む、骨損傷治療用キット。 - 請求項1~15のいずれか1項に記載のインプラントを骨損傷部位に適用することを含む、骨損傷部位の治療方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780047315.3A CN109562201A (zh) | 2016-07-25 | 2017-07-25 | 用于治疗骨损伤部位的植入物和试剂盒、以及骨损伤部位的治疗方法 |
JP2018529923A JPWO2018021333A1 (ja) | 2016-07-25 | 2017-07-25 | 骨損傷部位の治療のためのインプラント及びキット、並びに骨損傷部位の治療方法 |
KR1020197002411A KR20190022742A (ko) | 2016-07-25 | 2017-07-25 | 골 손상 부위의 치료를 위한 임플란트 및 키트, 그리고 골 손상 부위의 치료 방법 |
EP17834335.6A EP3488877A4 (en) | 2016-07-25 | 2017-07-25 | IMPLANT AND KIT FOR TREATING BONE LESION SITES AND METHOD FOR TREATING LESION SITES |
US16/319,998 US20190269828A1 (en) | 2016-07-25 | 2017-07-25 | Implant and kit for treatment of bone lesion site, as well as method for treating bone lesion site |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016145829 | 2016-07-25 | ||
JP2016-145829 | 2016-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018021333A1 true WO2018021333A1 (ja) | 2018-02-01 |
Family
ID=61016036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/026905 WO2018021333A1 (ja) | 2016-07-25 | 2017-07-25 | 骨損傷部位の治療のためのインプラント及びキット、並びに骨損傷部位の治療方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190269828A1 (ja) |
EP (1) | EP3488877A4 (ja) |
JP (1) | JPWO2018021333A1 (ja) |
KR (1) | KR20190022742A (ja) |
CN (1) | CN109562201A (ja) |
WO (1) | WO2018021333A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019235543A1 (ja) * | 2018-06-05 | 2019-12-12 | 国立大学法人東京農工大学 | 多孔質体、及び、医療用材料 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL236359B1 (pl) | 2020-01-21 | 2021-01-11 | Politechnika Slaska Im Wincent | Sposób otrzymywania warstw polimerowych na powierzchni tytanu lub stopów tytanu |
PL237829B1 (pl) | 2020-01-21 | 2021-05-31 | Politechnika Slaska Im Wincent | Sposób otrzymywania warstw polimerowych na powierzchni tytanu lub stopów tytanu na bazie polimeru z lekami |
PL236821B1 (pl) | 2020-01-21 | 2021-02-22 | Politechnika Slaska Im Wincent | Sposób otrzymywania warstw polimerowych na powierzchni tytanu lub stopów tytanu na bazie polimeru z tlenkami |
PL236823B1 (pl) | 2020-01-21 | 2021-02-22 | Politechnika Slaska Im Wincent | Sposób otrzymywania warstw polimerowych na powierzchni tytanu lub stopów tytanu na bazie polimeru z fosforanami |
RU2768571C1 (ru) * | 2020-12-21 | 2022-03-24 | Акционерное Общество "Наука И Инновации" | Скаффолд для замещения костных дефектов |
CN113171224B (zh) * | 2021-04-08 | 2022-06-28 | 浙江大学 | 一种促进骨损伤修复的植入绷带及制备方法 |
CN115105641B (zh) * | 2022-06-20 | 2023-06-02 | 四川大学 | 一种可骨性愈合连接的皮下植入材料 |
CN115446547B (zh) * | 2022-09-16 | 2024-06-04 | 景德镇陶瓷大学 | 一种钛网板渐进成形方法和脑颅骨修复体的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63196286A (ja) * | 1987-02-12 | 1988-08-15 | Sumitomo Electric Ind Ltd | 細胞培養用基材 |
JPS63198978A (ja) * | 1987-02-13 | 1988-08-17 | Sumitomo Electric Ind Ltd | 細胞培養用基材 |
WO2003018077A1 (fr) * | 2001-08-22 | 2003-03-06 | National Institute Of Advanced Industrial Science And Technology | Procede de regeneration osseuse |
JP2014004327A (ja) * | 2012-05-31 | 2014-01-16 | Yoshinori Kuboki | チタン−タンパク質複合体、生体インプラントおよび細胞培養基材 |
WO2015012415A1 (ja) * | 2013-07-26 | 2015-01-29 | 宇部興産株式会社 | 細胞の培養方法、細胞培養装置及びキット |
WO2016121771A1 (ja) * | 2015-01-26 | 2016-08-04 | 宇部興産株式会社 | 骨髄類似構造を利用した細胞培養法、及び骨損傷部位の治療のためのポリイミド多孔質膜 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2238992B1 (en) * | 2008-01-28 | 2014-05-14 | NGK Spark Plug Co., Ltd. | Biological implant having a foamed surface and method of producing the same |
CN101874751B (zh) * | 2009-04-30 | 2013-07-10 | 复旦大学 | 一种多层多孔支架及其制备方法 |
WO2014041516A1 (en) * | 2012-09-14 | 2014-03-20 | Ecole Polytechnique Federale De Lausanne (Epfl) | Biocompatible multi-layered structure comprising foam layers and a functional interface |
-
2017
- 2017-07-25 EP EP17834335.6A patent/EP3488877A4/en not_active Withdrawn
- 2017-07-25 WO PCT/JP2017/026905 patent/WO2018021333A1/ja unknown
- 2017-07-25 US US16/319,998 patent/US20190269828A1/en not_active Abandoned
- 2017-07-25 CN CN201780047315.3A patent/CN109562201A/zh active Pending
- 2017-07-25 KR KR1020197002411A patent/KR20190022742A/ko not_active Application Discontinuation
- 2017-07-25 JP JP2018529923A patent/JPWO2018021333A1/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63196286A (ja) * | 1987-02-12 | 1988-08-15 | Sumitomo Electric Ind Ltd | 細胞培養用基材 |
JPS63198978A (ja) * | 1987-02-13 | 1988-08-17 | Sumitomo Electric Ind Ltd | 細胞培養用基材 |
WO2003018077A1 (fr) * | 2001-08-22 | 2003-03-06 | National Institute Of Advanced Industrial Science And Technology | Procede de regeneration osseuse |
JP2014004327A (ja) * | 2012-05-31 | 2014-01-16 | Yoshinori Kuboki | チタン−タンパク質複合体、生体インプラントおよび細胞培養基材 |
WO2015012415A1 (ja) * | 2013-07-26 | 2015-01-29 | 宇部興産株式会社 | 細胞の培養方法、細胞培養装置及びキット |
WO2016121771A1 (ja) * | 2015-01-26 | 2016-08-04 | 宇部興産株式会社 | 骨髄類似構造を利用した細胞培養法、及び骨損傷部位の治療のためのポリイミド多孔質膜 |
Non-Patent Citations (6)
Title |
---|
ILMARINEN, T. ET AL.: "Ultrathin Polyimide Membrane as Cell Carrier for Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelium", PLOS ONE, vol. 10, no. 11, 2015, pages e0143669, XP055457529 * |
NAGANO, M. ET AL.: "Bone bonding ability of an apatite-coated polymer produced using a biomimetic method: A mechanical and histological study in vivo", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 31, 1996, pages 487 - 494, XP055457539, ISSN: 0021-9304 * |
NOREIKAITE, A. ET AL.: "Scaffold design for artificail tissue with bone marrow stem cells", MEDICINA, 13 July 2017 (2017-07-13), XP055457541, ISSN: 1010-660X * |
See also references of EP3488877A4 * |
TAO, C.T. ET AL.: "Polyetherimide membrane formation by the cononsolvent system and its biocompatibility of MG 63 cell line", JOURNAL OF MEMBRANE SCIENCE, vol. 269, 2006, pages 66 - 74, XP024931301, ISSN: 0376-7388 * |
VAN VLIERBERGHE, S. ET AL.: "Surface Modification of Polyimide Sheets for Regenerative Medicine Applications", BIOMACROMOLECULES, vol. 11, 2010, pages 2731 - 2739, XP055457534, ISSN: 1525-7797 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019235543A1 (ja) * | 2018-06-05 | 2019-12-12 | 国立大学法人東京農工大学 | 多孔質体、及び、医療用材料 |
JPWO2019235543A1 (ja) * | 2018-06-05 | 2021-07-29 | 国立大学法人東京農工大学 | 多孔質体、中空材料、人工血管、及び、医療用材料 |
JP7392952B2 (ja) | 2018-06-05 | 2023-12-06 | 国立大学法人東京農工大学 | 多孔質体、中空材料、人工血管、及び、医療用材料 |
Also Published As
Publication number | Publication date |
---|---|
KR20190022742A (ko) | 2019-03-06 |
CN109562201A (zh) | 2019-04-02 |
EP3488877A1 (en) | 2019-05-29 |
US20190269828A1 (en) | 2019-09-05 |
EP3488877A4 (en) | 2020-03-25 |
JPWO2018021333A1 (ja) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018021333A1 (ja) | 骨損傷部位の治療のためのインプラント及びキット、並びに骨損傷部位の治療方法 | |
Xu et al. | A silk fibroin/collagen nerve scaffold seeded with a co-culture of Schwann cells and adipose-derived stem cells for sciatic nerve regeneration | |
Salehi et al. | Efficient mineralization and osteogenic gene overexpression of mesenchymal stem cells on decellularized spinach leaf scaffold | |
Zeinali et al. | Preparation and characterization of graphene oxide aerogel/gelatin as a hybrid scaffold for application in nerve tissue engineering | |
Chen et al. | NSC-derived extracellular matrix-modified GelMA hydrogel fibrous scaffolds for spinal cord injury repair | |
EP3489351A1 (en) | Cell cultivation method, suspended cell elimination method, and method to kill suspended cells | |
KR20190022706A (ko) | 세포 배양 모듈 | |
US10508264B2 (en) | Cell culture method using bone marrow-like structure, and porous polyimide film for healing bone injury site | |
Abazari et al. | Acceleration of osteogenic differentiation by sustained release of BMP2 in PLLA/graphene oxide nanofibrous scaffold | |
Chun et al. | Nanostructured bladder tissue replacements | |
Mounesi Rad et al. | Preparation of HMWCNT/PLLA nanocomposite scaffolds for application in nerve tissue engineering and evaluation of their physical, mechanical and cellular activity properties | |
JP6969614B2 (ja) | 細胞培養装置、及びそれを使用した細胞培養方法 | |
JP6907477B2 (ja) | 細胞培養方法及び細胞培養装置 | |
KR101961580B1 (ko) | 물질의 생산 방법 | |
JP2021090436A (ja) | 神経幹細胞の分化を抑制する方法、神経幹細胞を調製する方法、及び神経幹細胞を分化誘導する方法 | |
WO2018021362A1 (ja) | 脱分化しやすい細胞の脱分化を抑制する方法、当該細胞の調製方法、及び物質の産生方法 | |
WO2021029409A1 (ja) | 小片多孔膜を適用した細胞培養法 | |
WO2021029408A1 (ja) | エクソソームの産生方法 | |
JP2024071498A (ja) | スキャフォールドフリー三次元軟骨組織体を製造する方法、スキャフォールドフリー三次元軟骨組織体、及びスキャフォールドフリー三次元軟骨組織体を製造するためのモジュール化ポリイミド多孔質膜 | |
KR20160016687A (ko) | 이식용 그래핀-나노 파이버 지지체 뇌질환 응용기술 및 상기 그래핀 나노 파이버 지지체 추적용 광음향 영상 기술 | |
KR20190022695A (ko) | 세포 배양 장치 및 그것을 사용한 세포 배양 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17834335 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20197002411 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018529923 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017834335 Country of ref document: EP Effective date: 20190225 |